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ABSTRACT OF THE DISSERTATION 
Immune Dysregulation and Pancreatic Cancer:  
 Overactivity, Inflammation and Epigenetic Modifications of Immune Function 
 
by 
 
Brian Huang 
Doctor of Philosophy in Epidemiology 
University of California, Los Angeles, 2019 
Professor Zuofeng Zhang, Chair 
 
Background: Pancreatic cancer is a highly lethal malignancy that is often diagnosed at advanced 
stages where treatment options are limited and prognosis is poor. As the immune system is 
intricately involved in the detection, elimination, and initiation of cancer, there has been major 
interest in understanding the role of immune dysregulation in the development of pancreatic 
cancer. Conditions associated with immune overactivity (e.g. allergies), chronic inflammation 
(e.g. type 2 diabetes, metabolic syndrome) and the epigenetic modification of immune genes 
(e.g. cytokines) may perhaps provide insight into the underlying mechanisms of pancreatic 
carcinogenesis. Past retrospective epidemiological studies have observed inverse associations 
between allergies and pancreatic cancer risk, but this finding has not been detected in prospective 
studies. In addition, the relationship between type 2 diabetes onset and pancreatic cancer risk has 
not been well explored in racially/ethnically diverse populations. Metabolic profiles of diabetes 
patients and pancreatic cancer risk have similarly not been evaluated in non-white individuals. 
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Finally, there is limited literature on the influence of methylation in cytokine genes and 
pancreatic cancer progression. 
Objectives and Specific Aims: The objective of this dissertation is to further elucidate the 
influence of atopic allergic conditions, type 2 diabetes, and methylation of cytokine genes on 
pancreatic cancer risk and survival. The specific aims were: 1) to conduct a prospective analysis 
of atopic allergic conditions (AACs) and the treatment of these conditions on pancreatic cancer 
risk in a multiethnic population; 2) to investigate the association between type 2 diabetes onset 
and pancreatic cancer risk in a racially diverse patient-based cohort, and to establish a metabolic 
profile of diabetes patients who are at high risk of developing pancreatic cancer; and 3) to 
evaluate the relationship between the methylation of cytokine genes in pancreatic cancer tumors 
and overall survival.  
Methods: For specific aim 1, we analyzed prospective data from 187,266 participants from the 
Multiethnic Cohort (MEC). Information on AACs and antihistamine medication use was 
assessed via a baseline questionnaire when individuals joined the MEC in 1993-1996. Adjusted 
risk ratios (RRs) and 95% confidence intervals (CIs) for pancreatic cancer incidence by AACs 
and antihistamines were estimated using Cox regression models, adjusting for age, sex, ethnicity, 
education, smoking status, family history of pancreatic cancer, body mass index, diabetes, and 
alcohol intake. We further evaluated associations among subgroups defined by age, sex, 
ethnicity, follow-up time, and known pancreatic cancer risk factors. For specific aim 2, we 
conducted a retrospective cohort study of 1,499,627 patients from Kaiser Permanente Southern 
California (KPSC) from 2006-2016. Diabetes patients were identified using glucose and 
hemoglobin A1c (HbA1c) measurements based on diagnostic criteria by the American Diabetes 
Association (ADA). We used Cox regression with time-varying exposures to assess the 
relationship between diabetes status/duration and pancreatic cancer. For individuals with incident 
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diabetes, we evaluated longitudinal changes in glucose, HbA1c and weight measurements 
leading up to the diabetes diagnosis between those with and without pancreatic cancer. We 
further performed Cox proportional hazards regression to examine the associations between the 
percent differences in glucose, HbA1c and weight and pancreatic cancer risk. All models 
included gender, race/ethnicity, smoking, BMI, alcohol use, family history of pancreatic cancer, 
history of pancreatitis, and education as covariates. For specific aim 3, we performed a 
retrospective cohort study of 162 pancreatic cancer patients from The Cancer Genome Atlas 
(TCGA). We evaluated methylation on CpG probes in proximity to seven genes: IL10, IL6, IL8, 
TGFβ1, TGFβ2, TGFβ3, and TNF. Methylation was assessed using the Illumina Infinium 
HumanMethylation450 (HM450) BeadChip methylation assay. We used Cox proportional 
hazards regression to evaluate the relationship between site- and region-specific DNA 
methylation and pancreatic cancer survival, adjusting for age, gender, stage and five independent 
surrogate variables associated with potential confounders measured with error (smoking, receipt 
of radiation, sample plate). We assessed the relationship between methylation at each given 
site/region and the expression of the gene in closest proximity using the Spearman’s correlation 
coefficient. 
Results: For specific aim 1, 1,455 incident cases of pancreatic cancer were identified among the 
white, African American, Latino, Japanese American and Native Hawaiian participants of the 
MEC with an average 16-year follow-up. AACs (relative risk/risk ratio [RR] 1.00, 95% CI 0.88-
1.12) and antihistamines (RR 0.92, 95% CI 0.78-1.07) were not clearly associated with 
pancreatic cancer incidence. While these associations were also null for most subgroups, we did 
observe inverse associations of AACs (RR 0.74, 95% CI 0.56-0.98) and antihistamines (RR 0.66, 
95% CI 0.45-0.96) among the oldest participants (70+). For specific aim 2, we identified 2,002 
incident cases of pancreatic cancer among the white, African American, Latino and Asian 
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members of KPSC with 7.5 million person-years of follow-up. Compared to those without 
diabetes, individuals with incident diabetes and shorter diabetes durations (≤1 year: RR 6.91, 
95% CI 5.76-8.30; >1 year: RR 1.96, 95% CI 1.62-2.38) had the highest risk of pancreatic 
cancer. Among incident diabetes patients, those with pancreatic cancer had steeper increases of 
glucose, HbA1c and greater weight loss during the time prior to diabetes. Racial/ethnic 
differences in metabolic changes by pancreatic cancer status were observed, with more 
pronounced differences in Asians and blacks for glucose, in blacks and whites for HbA1c, and in 
Asians and whites for weight (p-values for heterogeneity ≤0.01). For specific aim 3, we observed 
poorer survival for increased methylation in several CpG probes in TGFβ1 (cg03313751: hazard 
ratio [HR] 1.62, 95% CI 1.14-2.31), TGFβ2 (cg16658719: HR 1.58, 95% CI 1.21-2.06), TGFβ3 
(cg16292972: HR 1.45, 95% CI 1.01-2.09) and IL6 (cg15703690: HR 1.03, 95% CI 1.00-1.05), 
specifically those near transcription start sites. Conversely, higher methylation in one CpG locus 
in IL10 (cg14789529: HR 0.97, 95% CI 0.94-1.00) was associated with increased survival. 
Conclusions: Our study provides additional evidence of the intricate relationships between 
immune dysregulation and pancreatic cancer risk and progression. The findings for atopic 
allergic conditions support the null association for pancreatic cancer observed in prior 
prospective cohorts. Moreover, increased pancreatic cancer risk for new-onset diabetes is 
observed among racial/ethnic minorities, while the metabolic profiles for incident diabetes 
patients appear to vary by pancreatic cancer status and race/ethnicity. Lastly, epigenetic 
alterations and regulation of cytokine-related gene expression may be involved in the progression 
of pancreatic cancer.  
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CHAPTER 1. BACKGROUND 
 
1.1 Pancreatic Cancer 
1.1.1 Overview 
Pancreatic cancer is a malignancy in the exocrine and endocrine cells of the pancreas. 
Cancers of the exocrine cells are the most prevalent, with adenocarcinoma making up 95% of all 
exocrine cancers1,2. Less common exocrine tumors include adenosquamous, squamous cell, 
signet ring cell and undifferentiated carcinomas. Malignancies in the endocrine cells, called 
pancreatic neuroendocrine tumors (NETs), are fairly rare and comprise less than 5% of all 
pancreatic cancers1.  
 
1.1.2 Pancreatic Cancer Incidence & Mortality 
Pancreatic cancer is the 12th most common cancer and 7th leading cancer-related death in 
the world3. According to GLOBOCAN estimates, there were approximately 458,918 new cases 
and 432,242 deaths in 2018. Pancreatic cancer is more frequently diagnosed in males (243,033 
males cases vs. 215,885 female cases in 2018) and in developed regions, such as Western 
Europe, North America and Australia4. Due to inadequate screening, most cases are diagnosed at 
advanced stages where treatment options are scare and offer limited benefit2. As over 90% of 
cases die from the disease5, patterns for mortality are similar to those for incidence across gender 
and geographic region3. Five-year survival rates differ by region and range from roughly 4.4% in 
Russia, to 10-15% in Canada, China, Australia and many European countries, to 23.6% in 
Kuwait from 2000-20146. Survival rates have had minor increases (3-5%) over the past years in 
several countries6,7.  
In the United States, pancreatic cancer is the 10th most commonly diagnosed malignancy 
and 3rd leading cause of cancer death. The American Cancer Society estimates that there will be 
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56,770 new cases and 45,750 deaths from pancreatic cancer in 20198. Furthermore, pancreatic 
cancer has the lowest survival of all cancers with an overall five-year survival rate of 9% from 
2008-2014. Survival varies widely by stage at diagnosis, from 34% for localized tumors to 3% 
for distance stage tumors8.  
Incidence and death rates for pancreatic cancer in the United States have increased 
moderately in recent years. The American Cancer Society reports that the incidence rate 
increased by 0.9% per year for men and 1.0% per year for women from 2005-2014, while the 
mortality rate increased by 0.3% per year for men and had no change per year for women from 
2006-20159. Due to advancements in the screening and treatment for breast and colorectal 
cancers, pancreatic cancer is expected to become the second leading cause of cancer-related 
death by 203010. Five-year survival rates have also improved slightly, from a rate of 4% in the 
late 1980’s to the current rate of 9%8,11. Despite this, overall survival is still fairly dismal and 
more efforts are needed improve the outcomes of patients with pancreatic cancer. For instance, 
recent literature has suggested that genomic tumor sequencing could offer potential clinical 
benefits by identifying molecular subtypes of pancreatic cancer that are more responsive to 
certain therapies12,13. 
 
1.1.3 Pancreatic Cancer Risk Factors 
Modifiable lifestyle risk factors for pancreatic cancer include smoking, obesity and heavy 
alcohol use7,14,15. Smoking is a major contributor and accounts for approximately 20-30% of all 
pancreatic cancer cases14,16,17. Current smokers have around a two-fold increased risk compared 
to never smokers and this susceptibility increases with the intensity and duration of 
smoking14,16,18. Additionally, cancer risk increases by 10% per 5-unit increase in body mass 
index, corresponding to a 20% elevated risk for obese individuals compared to normal weight 
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individuals19,20. Heavy alcohol drinking has also been reported to increase pancreatic cancer 
susceptibility by approximately 20%21–23.  
Pancreatic cancer is more commonly diagnosed among older individuals, males, African 
Americans and diabetics14. The average age of onset is 71 and about two-thirds of cases are over 
65 years old. Higher pancreatic cancer rates in males and blacks may be explained by the greater 
prevalence of other risk factors (e.g. smoking, diabetes, obesity) in these groups14. Several meta-
analyses have reported a doubled risk of pancreatic cancer among type 2 diabetics compared to 
non-diabetics24,25. Other non-modifiable risk factors include non-O blood type, Helicobacter 
pylori infection, chronic pancreatitis, family history, and inherited familial genetic mutations15. 
Chronic pancreatitis affects about <1% of the population and has been associated with a two- to 
six-times increase in pancreatic cancer susceptibility15,26. Furthermore, pancreatic cancer risk 
increases substantially with the number of relatives with past malignancy5. Inherited genetic 
syndromes, which constitute about 10% of all pancreatic cancers, include familial pancreatitis 
(PRSS1), Peutz-Jeghers syndrome (STK11), familial atypical multiple mole melanoma 
syndrome (p16), hereditary non-polyposis colorectal cancer (MLH1, MSH2) and hereditary 
breast and ovarian cancer syndrome (BRCA1/2, PALB2)5,14. 
 
1.2 Immune Dysregulation and Pancreatic Cancer 
1.2.1 Overview 
As in many other cancers, the immune system is involved in several mechanisms that 
may influence the development and progression of pancreatic cancer27–30. Chronic inflammation 
has been recognized as a key pathway in pancreatic tumorigenesis, where pro-inflammatory 
cytokines and transcription factors induce cell transformation via recurring cycles of DNA 
damage, inhibited apoptosis and cell proliferation27. Concurrently, the innate and adaptive 
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immune systems engage in active immunosurveillance to identify and eliminate damaged and 
dysregulated cells before they become malignant28. However, cancer cells that are less 
immunogenic can escape detection and subsequently promote further growth by modulating 
immune function and impairing anti-tumor processes28–30. Pancreatic cancers cells can evade the 
immune system by directly releasing anti-inflammatory cytokines, such as IL-10 and TGF-β, and 
expressing immune-inhibitory cell surface molecules such as PD-L129. These mechanisms create 
an immunosuppressed microenvironment that favors tumor progression, characterized by 
increased regulatory cells and inactivated immune effector cells29. 
Given these intricate pathways, the dysregulation of the immune system can perhaps 
compromise its ability to recognize and control cancer progression. Immune overactivity, 
chronic low-grade inflammation, and epigenetic modification of immune function may thus be 
important indicators for pancreatic cancer risk and development. In particular, this dissertation 
will evaluate the influence of atopic allergic conditions, diabetes onset and duration, and 
methylation of cytokine-related genes on pancreatic cancer incidence and survival (see Figure 1 
for conceptual model).  
 
1.2.2 Atopic Allergic Conditions (AACs) 
Atopic allergic conditions (AACs) are comprised of multiple syndromes including 
asthma, hay fever/rhinitis, skin allergies and food allergies. It affects over 50 million individuals 
in the United States per year, and nearly 30% of adults and 40% of children suffer from some 
type of allergic condition31. Family history, sensitization to aeroallergens, respiratory virus 
infections, and air pollutions are among the known risk factors for AACs32.  
Allergies have been theorized to increase cancer risk through chronic inflammation or 
reduce risk via enhanced immunosurveillance, with the exact mechanism appearing to vary by 
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malignancy type33. There has been support for the immunosurveillance pathway in regards to 
pancreatic cancer, as several retrospective studies have observed inverse associations for allergic 
conditions34,35. In a recent meta-analysis of fourteen case-control studies with a total of 5,550 
cases, summary estimates revealed protective associations for asthma, nasal allergies and skin 
allergies with pancreatic cancer risk34. While most of the individual studies in the meta-analysis 
showed reduced risks for nasal allergies, there was less agreement across the studies for skin 
allergies and asthma34. Asthma has also been assessed in several registry-based retrospective 
cohorts from Finland and Sweden, which have yielded conflicting results36–38. 
In contrast, there has been a scarcity of prospective evidence regarding this relationship. 
To date, there have only been four prospective cohorts examining AACs and pancreatic cancer, 
all of which have had findings inconsistent with those of the case-control studies39–42. Three out 
of the four cohorts observed null associations between pancreatic cancer and conditions such as 
asthma, hay fever, and dermal reactions39–41, while the fourth cohort study observed an increased 
risk for asthma but a null association for skin allergies42. These four cohorts, however, were 
conducted in mainly Caucasian populations. The two larger cohorts were also conducted among 
special populations of 34,000 Seventh-Day Adventists and 29,000 male smokers from 
Finland40,42. Moreover, none of these cohorts evaluated whether allergy-treating medications 
were related to pancreatic cancer incidence. Given the current literature, the influence of AACs 
and the treatment for such conditions on pancreatic cancer risk has not been prospectively 
investigated in a large heterogeneous population or within particular ethnic groups.  
 
1.2.3 Type 2 Diabetes Onset 
Type 2 diabetes is a metabolic disorder associated with chronic low-grade inflammation 
and immune imbalance43,44. Diabetics have been observed to have higher levels of inflammatory 
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responses due to the dysregulation of both innate and adaptive immune systems43–46. This 
chronic inflammatory environment may hence play a role in the development of pancreatic 
malignancy. Diabetes-related conditions such as insulin resistance and hyperglycemia may also 
influence the risk of pancreatic cancer. Prior literature has suggested that higher levels of insulin 
may support cancer cell proliferation through various signaling pathways47,48. In addition, 
hyperglycemia promotes pancreatic cancer growth by providing glucose for tumor cells49,50. 
Higher levels of glucose also activate the transcription factor NF-κB, which is involved in 
several inflammatory pathways and the disruption of normal cell cycle regulation27.  
Type 2 diabetes has been recognized as a risk factor for pancreatic cancer in 
epidemiologic studies25. However, diabetes may also be a manifestation of the pancreatic tumor 
itself, as supported by evidence showing that the prevalence of new-onset diabetes is higher 
among pancreatic cancer cases51. Furthermore, cases with recently diagnosed diabetes appear to 
have improved glucose metabolism and control following tumor resection52,53. Although still 
unclear, current literature suggests that individuals with recent-onset diabetes have a higher 
pancreatic cancer risk compared to those with long-standing diabetes25,51,54. 
 To date, the relationship between recent-onset diabetes and pancreatic malignancy has 
been mainly explored in either case-control studies55 or within cohorts of primarily Caucasian 
individuals56–59. Furthermore, a majority of the cohort studies consisted solely of diabetes 
patients and could only report a standardized incidence ratio because they lacked a non-diabetes 
comparison group57–59. Recently, in the prospective Multiethnic Cohort Study, African 
Americans and Latinos with recent-onset diabetes had elevated risks for pancreatic cancer 
compared to individuals with long-standing diabetes60. Other than these latest findings, however, 
research in ethnically diverse populations is still quite limited. 
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1.2.4 Methylation of Cytokine Genes 
Pancreatic cancers are capable of modulating the immune response and establishing an 
immunosuppressive microenvironment that promotes tumor growth. In this immune-inhibitory 
state, increased levels of T regulatory cells and myeloid derived suppressor cells impair the 
antitumor activity of effector cells such as cytotoxic CD8+ T cells, natural killer cells, and 
dendritic cells29. In addition, helper CD4+ T cells transition from a Th1 phenotype, which 
facilitates tumor-eliminating processes, to a Th2 phenotype, which supports more tumor-
tolerating immune responses29,61,62. Current literature suggests that pancreatic cancer patients 
with higher levels of T regulatory cells63, myeloid derived suppressor cells64 and Th2-type T 
helper cells65 have worse prognoses, while those with higher concentrations of immune effector 
cells have increased survival29,66,67.  
These changes in immune function are influenced in part by the aberrant expression and 
production of regulatory cytokines. Pancreatic tumors cells have been found to directly secrete 
the anti-inflammatory cytokines IL-10 and TGF-β, which skew T helper cell differentiation 
towards the Th2 phenotype and suppress tumor-killing Th1 responses62,68. Circulating levels of 
pro-inflammatory cytokines (e.g. IL-6, IL-8, TNF-α) have also been observed to be elevated in 
pancreatic cancer patients compared to normal controls69–72. Other studies have further detected 
increased genetic and protein expression of both pro-inflammatory (e.g. IL-1β, IL-6, IL-8, TNF-
α) and anti-inflammatory (e.g. IL-10, TGF-β, IL-11) cytokines by pancreatic cancer cells70,73–75. 
Given the complex interplay between cytokines and immune function, the expression and serum 
levels of various cytokines have been found to be predictive markers of pancreatic cancer 
progression in some small studies70–72,74–80 (Table 1-1).  
While serum and mRNA levels of cytokines have been evaluated in regard to survival, 
there is limited information as to whether prognosis is affected by the epigenetic regulation of 
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associated gene expression. DNA methylation is a form of epigenetic mark that involves the 
addition of a methyl group to cytosine bases at CpG dinucleotides. Aberrant DNA methylation 
patterns have been implicated in the development and progression of several cancers, perhaps by 
inducing genomic instability and altering gene expression to influence the tumor 
microenvironment81–85. Currently, research on DNA methylation and pancreatic cancer 
progression has been fairly nascent, and prior studies have been primarily epigenome-wide 
association studies (EWAS) or candidate gene studies that did not focus on genes related to the 
immune response86–92. Hence, it is unknown whether the immune dysfunction and poor 
prognosis observed in pancreatic cancer is attributed to the atypical methylation of cytokine-
related genes. Identifying and understanding these relationships could potentially identify 
methylation biomarkers of survival and allow for the development of novel methylation-targeted 
therapies. 
 
1.3 Gaps in Knowledge 
Despite several retrospective epidemiologic studies investigating allergies and pancreatic 
cancer, there is limited prospective evidence of this relationship from a multiethnic population. 
Likewise, the association between type 2 diabetes onset and pancreatic cancer incidence has not 
been evaluated within a large, racially diverse cohort. Lastly, no prior study has examined the 
impact of the methylation of cytokine genes on pancreatic cancer survival. 
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CHAPTER 2. RESEARCH OBJECTIVES 
 
2.1 Rationale and Objectives 
The purpose of this dissertation is to further understand the role of atopic allergic 
conditions and type 2 diabetes onset on the risk of pancreatic cancer, and the impact of 
methylation of cytokine genes on pancreatic cancer survival. Understanding the relationships 
between these factors and pancreatic cancer might further elucidate the impact of immune 
dysregulation on pancreatic cancer tumorigenesis and progression. In addition, this research may 
help identify potential immunotherapy targets for the prevention, control and treatment of the 
disease. 
 
2.2 Specific Aims and Hypotheses 
Aim 1: To conduct a prospective analysis of atopic allergic conditions and the treatment of these 
conditions on pancreatic cancer risk in a racially diverse population 
• Hypothesis 1: Compared to those without allergies, individuals with a history of allergies 
will have a decreased risk of pancreatic cancer because an overactive immune response may 
be more protective in eliminating cancer cells  
• Hypothesis 2: Compared to those without allergies, individuals with allergies who receive 
antihistamine treatment will have an increased risk of pancreatic cancer because these drugs 
may suppress the immune system and hinder its ability to eliminate cancer cells 
 
Aim 2: To investigate the association between type 2 diabetes onset and pancreatic cancer risk in 
a racially diverse patient-based cohort, and to establish a metabolic profile of diabetes patients 
who are at high risk of developing pancreatic cancer 
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• Hypothesis 1: Compared to those without diabetes, individuals with a history of type 2 
diabetes will have an increased risk for pancreatic cancer due to the carcinogenetic pathways 
involved in diabetes such as chronic inflammation, insulin resistance, and hyperglycemia 
• Hypothesis 2: Compared to those without diabetes, individuals with shorter diabetes 
durations will have an increased risk for pancreatic cancer because the new-onset diabetes 
may be a symptom of the pancreatic cancer tumor itself 
 
Aim 3: To evaluate the relationship between the methylation of cytokine genes measured on 
pancreatic tumor tissues and overall survival  
• Hypothesis: Individuals with tumor samples with epigenetic profiles that favor the 
expression of immune-inhibitory cytokines (e.g. IL-10, TGF-β) will have poorer survival 
compared to those without this epigenetic profile because immune-inhibitory cytokines could 
possibly create a pro-tumor microenvironment  
 
See Figure 1-1 for conceptual framework of dissertation aims.  
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CHAPTER 3. SPECIFIC AIM 1 – ATOPIC ALLERGIC CONDITIONS 
 
3.1 Methods 
3.1.1 Study population 
The Multiethnic Cohort Study was established in 1993-1996 to study cancer and chronic 
disease etiology among individuals living in California (mostly Los Angeles County) and 
Hawaii. It consists of roughly 215,000 participants ages 45-75 of five primary ethnic groups: 
white, African American, Latino, Japanese American and Native Hawaiian93. Upon enrollment, 
cohort members completed a 26-page baseline questionnaire, which included questions on 
demographics, lifestyle factors, personal medical conditions and family history of cancer.  
 Cohort members were excluded if they were not in the five main ethnic groups, had a 
previous history of pancreatic cancer prior to cohort entry, or were missing information on AAC 
status and pancreatic cancer risk factors (e.g. smoking, diabetes). The participants of the study 
were followed from the date of the baseline questionnaire to pancreatic cancer diagnosis, death, 
or the closure date of follow-up on December 31, 2012. Incident, invasive pancreatic cancer 
cases were identified by annual linkage with the statewide Surveillance, Epidemiology, and End 
Results (SEER) registries of Hawaii and California. Mortality information was obtained through 
linkage with states’ death certificate files and the National Death Index. 
 
3.1.2 Exposure assessment  
Participants were asked to self-report on the baseline questionnaire whether a physician 
had ever informed them that they had “asthma, hay fever, skin allergy, food allergy or any other 
allergy,” asked as a single combined exposure on the baseline questionnaire. In addition, 
participants were asked whether they had used any antihistamine medications (“allergy pills or 
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shots”) for “at least two times per week for one month or longer” and the duration at which they 
used these medications.  
History of AACs was assessed as a binary exposure. Antihistamine medication was 
analyzed as ever use and duration of use (none, ≤5 years, >5 years). We also combined these 
exposures to create an index of allergy severity (no AACs, AACs with no medication use, AACs 
with medication use). 
 
3.1.3 Statistical analyses  
 Baseline characteristics were compared across individuals with and without AACs using 
a t-test for age and chi-square tests for all other variables. Pancreatic cancer incidence rates, 
truncated to ages 45-95, were computed within the MEC, age standardized by 5-year age groups 
to the United States Census 2000 standard population.  
The influence of AACs and antihistamine use on pancreatic cancer incidence was 
evaluated using Cox proportional hazards regression models with time since baseline as the time 
metric. We used separate models to evaluate the associations between each of our exposures of 
interest (history of AACs, ever use of antihistamine, duration of antihistamine use, and allergy 
severity) and pancreatic cancer. We fit minimally adjusted models that included age at cohort 
entry, sex, and race/ethnicity (white, African American, Latino, Japanese American, Native 
Hawaiian) as strata variables, as well as fully adjusted models that also included smoking status  
(never, past, current), family history of pancreatic cancer, diabetes, education (≤12 years, some 
college/vocational, college graduate), alcohol intake (none, <24, 24-48, >48 g/day), and body 
mass index (BMI) (<25, 25-30, ≥30 kg/m2) as covariates. We also ran models with continuous 
measurements for alcohol intake and BMI and pack-year information for smoking and observed 
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no change in the results; thus, only findings from the original models are presented. Individuals 
were censored at death or end of follow-up. 
To assess effect modification of the associations of AACs or ever use of antihistamine 
medication on pancreatic cancer, we ran additional models among subgroups defined by age 
group (<50, 50-54, 55-59, 60-64, 65-69, 70+), sex, ethnicity, follow-up time since baseline (<5 
years, ≥5 years), and known/potential pancreatic cancer risk factors (cigarette smoking, family 
history of pancreatic cancer, diabetes, alcohol use, BMI). For AACs, we also ran models 
stratified by antihistamine use (ever, none). We tested for heterogeneity by fitting a separate 
model with a cross-product term for the exposure (history of AACs or ever use of antihistamine 
medication) and the stratifying variable. The proportional hazards assumption was assessed using 
Schoenfeld residuals while model fit was evaluated using Martingale and deviance residuals94. 
All analyses were conducted using SAS 9.3 (Cary, NC) and reported P values are two-sided. 
 
3.2 Results 
 After exclusions, the present study consisted of 187,226 total individuals (females 
N=101,845, males N=85,381). The mean age at cohort entry was 59.9 (standard deviation 8.8). 
Japanese American (28.7%), whites (25.0%), and Latinos (22.2%) were the most represented 
ethnicity groups, followed by African Americans (16.8%) and Native Hawaiians (7.3%). During 
an average follow-up period of 16.2 years, 1,455 incident cases were identified among 
participants at risk.  
Roughly one quarter of individuals reported a history of AACs (N=49,696, 26.5%). Age-
standardized pancreatic cancer incidence rates (left truncated at age 45) were lower in those with 
AACs (44.8 cases per 100,000) than in those without AACs (50.2 cases per 100,000) (Table 3-
1). Demographic characteristics and risk factors differed across individuals with and without 
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AACs. Those who reported having AACs tended to be younger, female, and white and were 
more likely to have a family history of pancreatic cancer and more years of education. 
Additionally, these individuals were less commonly diabetics, current smokers, or heavy alcohol 
drinkers (Table 1). Antihistamine medication use was reported in 28,413 (15.2%) participants. 
Among these individuals, 15,405 (54.2%) used antihistamines for five or less years. In regard to 
allergy severity, 15.0% of participants reported having AACs without antihistamine use and 
10.7% reported a history of both AACs and medication use (Table 3-1).  
In our models minimally adjusted for age, sex and race, we detected no significant 
associations between AACs, antihistamine use, or allergy severity with pancreatic cancer (Table 
3-2). However, we found a borderline protective association for those who had used 
antihistamines for five or less years (RR 0.81, 95% CI 0.65-1.00) compared to those who did not 
use any medications. All of the aforementioned associations were quite similar and non-
significant after including the remaining covariates in our fully adjusted models. Again, we 
observed a borderline reduced risk for individuals with five or less years of antihistamine use 
(RR 0.82, 95% CI 0.66-1.01) compared to those without any history of medication use (Table 3-
2).  
The null associations for AACs and ever use of antihistamines were present across all 
stratified analyses, except within the oldest individuals (age 70+) in the cohort (Tables 3-3 & 3-
4). Among individuals who were 70 or older at cohort entry, those who had a history of AACs 
had a 26% reduced risk (RR 0.74, 95% CI 0.56-0.98) while those who used antihistamines had a 
34% reduced risk (RR 0.66, 95% CI 0.45-0.96) of pancreatic cancer. In addition, AACs had a 
borderline protective association among those who were followed for less than five years (RR 
0.76, 95% CI 0.56-1.04). There were no associations of AACs and antihistamines within any of 
 15 
 
the other subgroups stratified by sex, ethnicity, BMI, family history of pancreatic cancer, 
smoking, diabetes, and alcohol use (Table 3-3 & 3-4). 
 
3.3 Discussion 
 In this prospective cohort study, we investigated the influence of atopic allergic 
conditions and antihistamine medication use on pancreatic cancer risk in a population of white, 
African American, Latino, Japanese American and Native Hawaiian individuals. After adjusting 
for covariates, we observed no clear association between any prior history of AACs, 
antihistamine use, or allergy severity with the incidence of pancreatic cancer. The null 
associations for AACs and antihistamine medication were consistent across subgroups defined 
by sex, ethnicity, follow-up time, BMI, family history, smoking status, diabetes and alcohol use. 
However, we did observe protective associations among those who were aged 70+ at cohort 
entry. While these findings may have resulted from censoring due to death, further evaluations of 
AACs and antihistamines on pancreatic cancer risk among older individuals might be 
worthwhile.  
 Four previous prospective cohorts have studied the association of AACs and pancreatic 
cancer. In these studies, the number of pancreatic cancer cases ranged between 4 and 172 and the 
resulting RR’s ranged from 0.59 to 2.1639–41. Thus, the null findings in these cohorts may have 
been attributed to insufficient statistical power. Though the largest number of cases came from 
the 29,000 Finnish male smokers from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Study, the results from this study cannot be easily extrapolated to the general population given 
the specificity of the study participants42. These cohort members were also at a higher baseline 
risk for pancreatic cancer given their shared smoking history95. Our results in the MEC agree 
with the null results of these past studies and, with nearly 1,500 cases from an ethnically diverse 
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population, provide more convincing evidence of a null association between overall allergies and 
pancreatic cancer.  
On the other hand, our findings conflict with the protective associations found in several 
case-control studies. This discrepancy may be due to differences in the participant selection 
across prospective and retrospective study designs. For instance, many of the case-control studies 
excluded a large proportion of cases due to death, refusal and non-response. Among the seven 
case-control studies that reported a decreased cancer risk for any allergic condition, nearly all 
were unable to recruit over half of the entire population of cases96–102. These exclusions could 
have introduced selection bias if the association of AACs and cancer risk was different across 
those enrolled and not enrolled in the studies. This is further supported by the fact that the 
strongest associations were observed in studies that recruited the lowest number of cases96,97. 
Though prospective cohorts are susceptible to selection bias due to loss of follow-up, our cohort 
was able to monitor the outcomes of all of our participants by passive linkage to the statewide 
SEER registry and National Death Index.  
Based on the existing literature, it appears that the influence of AACs on pancreatic risk 
may differ according to the type of allergy. Past case-control studies have showed fairly 
consistent inverse associations with hay fever and other nasal allergies34,96–99,101–103, but only a 
few studies have showed decreased risks for asthma34,100,103 and skin allergies99,100,103. While 
most studies had null findings for skin allergies and asthma, one retrospective cohort from 
Sweden found an increased pancreatic cancer risk among hospitalized asthma patients38, 
suggesting that disease severity may also play a role in carcinogenesis. For several studies that 
used a composite assessment of allergies, the protective overall associations seemed to be driven 
by the individual effects of hay fever and other nasal allergies96–99,101,102. Since we do not know 
the breakdown and prevalence of each allergic condition in the Multiethnic Cohort, our null 
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result could have been attributed to a condition that is not as strongly associated with pancreatic 
cancer. As hay fever represents a modest percentage of all atopic allergic conditions at roughly 
30%104,105, it is plausible that we could have missed a strong association in this subset.  
The mechanism in which allergies may impact cancer risk is still not well understood. 
AACs have been theorized to either decrease risk through heightened immunosurveillance or 
increase risk through chronic inflammation33. Although the protective associations from previous 
studies provide evidence for the immunosurveillance pathway, other studies have found no 
relationship between IgE levels, a biologic marker for allergic response, and pancreatic cancer 
risk106,107. Medical treatment of allergies may also modify the underlying mechanism, but there 
has been limited information regarding allergy medications and pancreatic cancer. Aside from 
our current analysis that detected no association of antihistamines, one other case-control study 
found protective associations among those who reported receiving medical treatment for 
allergies100. Another case-control study suggested that medication use may confound the 
association of allergies with pancreatic cancer, but did not conduct a formal analysis of this 
relationship98. In our study, we attempted to tease apart the interaction between allergies and 
medications with our allergy severity index, but did not observe any significant associations with 
this measurement.  
Other important factors in determining pancreatic cancer risk could possibly include the 
timing and duration of allergic conditions. In the recent PanGenEU case-control study, 
researchers found that participants who had post-childhood onset or ≥17 years of asthma had a 
reduced risk for pancreatic cancer34. Likewise, the Pancreatic Cancer Case-Control Consortium 
observed a stronger protective effect among individuals with late onset of allergic conditions 
compared to those with early onset108. We addressed timing of AACs in our cohort by examining 
duration of antihistamine use and performing subgroup analyses by follow-up time, since those 
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who had used medications for shorter lengths or completed the baseline questionnaire within five 
years may have had a more recent diagnosis of allergies. Hence, the borderline protective 
associations that we detected for the shorter periods of both antihistamine use and follow-up time 
may support the trend of a reduced risk among individuals with later onset allergies. In general, 
case-control studies would be more likely than prospective studies to catch more recent 
diagnoses of AACs since exposure assessment was done after identifying all cases and controls.  
One of the major strengths of this study is the large and heterogeneous sample, which 
allowed us to evaluate the relationship between AACs and pancreatic cancer in many different 
subgroups. In comparison to the previous four prospective cohorts, the present results are based 
on the greatest number of pancreatic cancer cases and are more generalizable to a heterogeneous 
population. We were also able to examine both medication use and an allergy severity index, 
which was not done in the past prospective cohorts. Since we collected epidemiologic data prior 
to disease diagnosis and linked to cancer registries with virtually complete case-ascertainment, 
our study is less susceptible to the recall and selection bias that may exist in case-control studies. 
However, we could have missed some pancreatic cases if the participant moved out of state and 
was not captured in the California or Hawaii tumor registries. Our assessment of AACs was also 
self-reported and combined into a non-specific single exposure, so we could not evaluate the 
influence of individual conditions or the duration of disease. Furthermore, we did not have any 
biological measurements (e.g. IgE) or information on the timing of AACs, limiting our ability to 
elucidate the detailed pathways in which allergies may impact risk. 
To our knowledge, this is the first study to examine the relationship between AACs and 
antihistamines with pancreatic cancer in a diverse and well-powered prospective setting. Our 
results are consistent with that of past prospective studies and provide additional support of a 
null association for overall AACs. Future prospective studies should aim to conduct a more 
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comprehensive assessment of specific AACs and allergy-treating medications on pancreatic 
cancer risk. 
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CHAPTER 4. SPECIFIC AIM 2 – TYPE 2 DIABETES ONSET 
 
4.1 Methods 
4.1.1 Study Population 
We conducted a retrospective cohort study of patients at-risk for pancreatic cancer from 
KPSC, an integrated health system comprising of 14 medical centers and over 200 medical 
offices throughout Southern California. KPSC’s diverse member population of over 4 million 
individuals is representative of the Southern California region, consisting of 45% whites, 23% 
Hispanics, 15% African Americans, 9% Asians and 7% other ethnicities109. All patient data, 
including information on outpatient and inpatient hospital visits, diagnosis codes, pharmacy 
prescriptions and laboratory tests, are stored in the electronic health record and regional data 
warehouse.  
Patients were eligible for the study if they met the following inclusion criteria during 
2006-2016: aged 45-90 years, at least two years of continuous membership in KPSC, and 
available information for body mass index (BMI), smoking status, and alcohol use. The two-year 
membership requirement was used to ensure that an individual had been in the KPSC health 
system long enough to establish an accurate medical history. Otherwise eligible patients were 
further excluded if they did not have a glucose (fasting, random or oral glucose tolerance) or 
hemoglobin A1c (HbA1c) measurement (N=67,486), were not in the four major race/ethnicity 
groups (Asian, non-Hispanic black, Hispanic, non-Hispanic white) (N=80,801), or had a prior 
diagnosis of pancreatic cancer (N=523) (Figure 1). The date of cohort entry was the January 1st 
of the first year after the patient met all inclusion criteria (e.g. if a patient met the final inclusion 
criterion in December 2006, the date of cohort entry would be January 1, 2007).  
This study was approved by the KPSC Institutional Review Board (IRB). 
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4.1.2 Exposure Assessment 
Individuals were identified as having diabetes if they had any of the following 
measurements based on the American Diabetes Association criteria: HbA1c ³6.5%, fasting 
glucose ³126 mg/dL, random glucose ³200 mg/dL or two-hour oral glucose tolerance test ³200 
mg/dL. The date of the earliest lab test within the diabetes range was treated as the diabetes 
diagnosis date. Diabetes status (prevalent, incident, vs. none) was defined based on the date of 
diabetes diagnosis in relation to cohort entry. Individuals were classified as prevalent cases of 
diabetes if their diabetes diagnosis was before or on the date of cohort entry and were 
categorized as incident cases of diabetes if the diagnosis was after cohort entry. For incident 
diabetes patients, we evaluated diabetes duration as incident diabetes ≤1 year and incident 
diabetes >1 year using the time elapsed since diabetes diagnosis. 
 
4.1.3 Assessment of Other Covariates 
Covariate data were obtained from most recent measurement or record prior to cohort 
entry. BMI was grouped into <25, 25-30, ³30 kg/m2, smoking was categorized as never, former, 
and current smoker, and alcohol use was treated as a dichotomous variable (yes vs. no). We used 
International Classification of Diseases (ICD) codes to identify patients with pancreatitis (ICD-9: 
577.0, 577.1; ICD-10: K85.x, K86.0, K86.1). Family history of pancreatic cancer (any relative) 
was attained from the patient history files and assessed as a dichotomous variable (yes vs. no). 
Information on education was obtained from the geocoding database109 and was categorized as 
completion of high school or less, some college, and college graduate. 
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4.1.4 Outcome 
Our primary outcome of interest was time from cohort entry to pancreatic cancer 
diagnosis. Patients in the final study cohort were censored at the first of the following: death, end 
of membership or end of study on December 31, 2016. Pancreatic cancer cases (ICD‐O‐3 codes 
C25.0‐C29.9) were identified from the internal KPSC cancer registry, which collects tumor 
characteristics such as date of diagnosis, tumor size, grade, and histology on all patients 
diagnosed with cancer and/or treated at KPSC since 1988. The KPSC registry reports to the 
Surveillance, Epidemiology and End Result (SEER) program and meets its high reporting 
standards110. Mortality information was obtained from inpatient records, the internal cancer 
registry and the California state death index. 
 
4.1.5 Statistical Analyses 
Baseline characteristics were compared across diabetes status using ANOVA for age and 
chi-square tests for all other variables. Pancreatic cancer incidence rates, age-standardized to the 
United States 2000 standard population and truncated to age 45+, were calculated for each 
diabetes group. 
The relationship between diabetes and pancreatic cancer incidence was analyzed using 
Cox proportional hazards regression. Both diabetes status (prevalent, incident vs. none) and 
duration (incident ≤1 year, incident >1 year, vs. none) were treated as time-varying exposures, 
which was assessed at each pancreatic cancer event for all members in the risk set. All models 
included age at cohort entry, gender, race/ethnicity, smoking, BMI, alcohol use, family history of 
pancreatic cancer, history of pancreatitis, and education as covariates.  
Additional analyses were conducted within subgroups defined by gender, race/ethnicity, 
BMI, smoking, alcohol use and pancreatitis. Heterogeneity was evaluated using models with an 
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additional interaction term for the exposure (diabetes status or duration) and subgroup variable of 
interest performed in the full sample.  
Schoenfeld residuals were used to confirm no violation of the proportional hazards 
assumption for each covariate, while Martingale and deviance residuals were used to evaluate 
model fit. All analyses were conducted using SAS 9.3 (Cary, NC). 
 
4.1.6 Mediation Analysis 
 To further understand the mechanisms in which diabetes may influence pancreatic cancer 
risk, we also examined whether diabetes mediated the associations for other pancreatic cancer 
risk factors. We performed a causal mediation analysis to examine whether diabetes acted as a 
mediator for smoking (former, current) and adiposity (overweight, obesity), as these factors may 
include diabetes in their causal mechanisms for pancreatic cancer. For each factor, we calculated 
the total effect, controlled direct effect not through diabetes, natural indirect effect through 
diabetes, and proportion mediated using the mediation analysis SAS macro developed for 
survival data111,112. This analysis was only performed among non- and incident diabetes patients 
to ensure that the smoking and adiposity risk factors preceded the onset of diabetes. 
 
4.1.7 Metabolic Profiling of Incident Diabetes Patients 
 To investigate which patients are at highest risk for pancreatic cancer, we evaluated 
metabolic profiles of incident diabetes patients at different timepoints of diabetes progression. 
Specifically, we examined fasting glucose, HbA1c and weight measurements at the time of 
diabetes diagnosis (closest record within 30 days before/after diagnosis) and during the period 
prior to diagnosis (closest record within 6 months to 2 years before diagnosis). We also 
calculated the percent difference and monthly rate of change between these two time windows 
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for each characteristic among individuals who had measurements in both periods (N=50,118 for 
glucose, N=23,936 for HbA1c, N=92,846 for weight). 
Metabolic characteristics were compared across incident diabetes patients with and 
without pancreatic cancer using Mann-Whitney U tests, as all non-weight associated 
measurements had right skewed distributions. As a sensitivity analysis, we also performed t-tests 
for the normally distributed weight variables and observed similar results as the Mann-Whitney 
U tests. We further performed Cox proportional hazards regression to examine the association 
between clinically meaningful percent differences (glucose: per 10% unit increase; HbA1c: per 
1% unit increase; weight: per 3% unit decrease) and monthly rates of change (glucose: per 
mg/dL/month increase; HbA1c: per 0.1%/month increase; weight: per kg/month decrease) and 
pancreatic cancer risk. In these models, individuals were followed from diabetes diagnosis to 
pancreatic cancer diagnosis, death, end of membership or end of the study. All models included 
age at diabetes diagnosis, gender, race/ethnicity, smoking and BMI as covariates, with smoking 
and BMI information obtained from the closest value prior to diabetes diagnosis.  
In order to assess whether these relationships differed by race/ethnicity, we performed 
subgroup analyses for the percent differences of glucose, HbA1c and weight. Within each 
subgroup, variations in the percent difference between patients with and without pancreatic 
cancer were evaluated using Mann-Whitney U tests. Overall heterogeneity by race/ethnicity was 
assessed using models of the percent difference regressed on pancreatic cancer status, 
race/ethnicity and an interaction term for pancreatic cancer and race/ethnicity. We used a linear 
regression for weight, which was fairly normally distributed, and a generalized linear model with 
a gamma distribution and log link for glucose and HbA1c due to right skewed distributions. We 
also performed separate Cox models to examine the relationships between percent difference or 
rate of change and pancreatic cancer incidence within each subgroup. We tested for 
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heterogeneity using a separate model with an additional interaction term for percent 
difference/rate of change and race/ethnicity.  
 
4.1.8 Sensitivity Analyses 
To assess the accuracy of the identification of incident diabetes, we re-ran all analyses 
dropping incident diabetes patients who did not have a prior metabolic test in the normal range. 
This did not exclude many individuals, as 97% of incident diabetes patients had a prior normal 
metabolic measurement. In order to address the potential effects of diabetes treatment, we also 
re-ran the metabolic profile analyses dropping individuals with metabolic measurements taken 
within the 30 days after diabetes diagnosis (N=15,589 for glucose, N=3,052 for HbA1c, 
N=25,337 for weight). Results were unchanged in both situations and thus we only present 
findings from the original models.  
 
4.2 Results 
 The final study cohort consisted of 1,499,627 patients at-risk for pancreatic cancer. The 
study population was on average 57.9 years old (standard deviation 10.9) and consisted of 55% 
females. Whites comprised nearly half of the cohort (45.7%), followed by Hispanics (32.5%), 
Asians (11.1%) and blacks (10.7%). From nearly 7.5 million person-years of follow-up, 2,002 
persons developed incident pancreatic cancer, translating to age-adjusted incidence rate of 30.7 
cases per 100,000 person-years.  
 Among the entire cohort, about 110,699 developed incident diabetes (7.4%), 332,939 had 
prevalent diabetes (22.2%) and 1,055,996 never had diabetes (70.4%). Age-adjusted incidence 
rates for pancreatic cancer were highest in patients with incident diabetes (43.7 cases per 100,000 
person-years), followed by patients with prevalent diabetes (41.2 cases per 100,000 person-
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years) and lowest in patients without diabetes (23.8 cases per 100,000 person-years). Prevalent 
and incident diabetes patients were more likely to be older, male, non-white, former smokers, 
and non-alcohol users. These individuals also tended to have higher BMI, lower education, and a 
prior diagnosis of pancreatitis (Table 4-1). Within the individual race/ethnicity groups, blacks 
(26.5%), Hispanics (25.2%) and Asians (24.6%) had the highest proportion of prevalent diabetes 
while blacks (9.2%) and Asians (8.9%) had the greatest proportion of incident diabetes. 
 
4.2.1 Diabetes Status/Duration and Pancreatic Cancer Risk 
Pancreatic cancer risk was elevated three times for patients with incident diabetes (RR 
3.17, 95% CI 2.75-3.65) and roughly two times for prevalent diabetes (RR 1.85, 95% CI 1.67-
2.05) compared to individuals without diabetes. When evaluating diabetes duration, we found 
that patients with incident diabetes with ≤1 year and >1 year of disease duration had almost 
seven times (RR 6.91, 95% CI 5.76-8.30) and two times (RR 1.96, 95% CI 1.62-2.38) the risk of 
pancreatic cancer, respectively, compared to individuals without diabetes. Similar patterns of 
associations for both diabetes status and duration were present across all race/ethnicity 
subpopulations (Table 4-2), as well as within subgroups of gender, BMI, smoking, and alcohol 
(Tables 4-3 & 4-4). 
 
4.2.2 Mediation Analysis 
In the mediation analysis, we observed that former and current smokers had a 38% (total 
effect RR 1.38, 95% CI 1.26-1.50) and 89% (total effect RR 1.89, 95% CI 1.60-2.25) higher risk 
of pancreatic cancer, respectively, compared to non-smokers. There was little mediation by 
diabetes and the controlled direct effect was similar for both former (RR 1.40, 95% CI 1.28-1.54) 
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and current (RR 1.97, 95% CI 1.79-2.17) smoking. Diabetes mediated 3.2% of the effect for 
former smoking and 2.4% of the effect for current smoking.  
 Moreover, we detected an 11% (total effect RR 1.11, 95% CI 1.02-1.20) increased risk of 
pancreatic cancer for overweight and a 25% (total effect RR 1.25, 95% CI 1.07-1.45) increased 
risk for obesity, compared to individuals with normal BMI. There was substantial mediation by 
diabetes for both overweight (proportion mediated 32.6%) and obesity (proportion mediated 
38.5%). For overweight, the controlled direct effect (RR 1.08, 95% CI 0.99-1.17) was about 
double of the indirect effect (RR 1.03, 95% CI 1.02-1.04) through diabetes. This pattern was 
similar for obesity, where the controlled direct effect (RR 1.16, 95% CI 1.06-1.26) was twice as 
large as the natural indirect effect (RR 1.08, 95% CI 1.05-1.12). 
 
4.2.3 Metabolic Profiling of Incident Diabetes Patients 
Among the 110,699 incident diabetes patients, 52.6% of incident diabetes patients had at 
least two fasting glucose measurements, 21.2% had at least two HbA1c measurements and 
89.5% had at least two weight measurements. Individuals who had at least two measurements 
tended to be older, female, non-smokers, and have lower BMI. 
Compared to those without pancreatic cancer, individuals who developed pancreatic 
cancer (N=306, 0.3%) had higher fasting glucose values at diabetes diagnosis (median 135.0 vs. 
131.0 mg/dL, p<0.0001), but not prior to diagnosis (106.0 vs. 106.0 mg/dL, p=0.87) (Figure 4-
2). When assessing changes between the two time windows, pancreatic cancer patients had a 
larger percent increase (median 27.4 vs. 19.8%, p<0.0001) and monthly rate of change (2.4 vs. 
1.6 mg/dL/month, p<0.0001) in their fasting glucose measurements. For HbA1c, pancreatic 
cancer patients had higher levels at diabetes diagnosis (median 6.8 vs. 6.6%, p<0.0001), but 
slightly lower levels in the period prior to diagnosis (6.1 vs. 6.2%, p<0.01) (Figure 4-2). The 
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percent difference (median 9.4 vs. 5.3%, p<0.0001) and monthly rate of change (0.05 vs. 
0.03%/month, p<0.001) between these two time periods were nearly double for individuals with 
pancreatic cancer. Weight was lower among pancreatic cancer cases compared to non-cases at 
diabetes diagnosis (median 79.8 vs. 85.3 kg, p<0.0001) and in the window prior to diagnosis 
(83.0 vs. 85.4 kg, p<0.01) (Figure 4-2). Additionally, there were greater decreases in the percent 
difference (median -2.0 vs. 0.0%, p<0.0001) and monthly rate of change (-0.2 vs. 0.0 kg/month, 
p<0.0001) in weight among individuals who developed pancreatic cancer compared to those who 
did not.  
 For all of the metabolic characteristics, the relationship between percent change over time 
and pancreatic cancer status appeared to vary by race/ethnicity. Pancreatic cancer patients had 
more pronounced percent increases in fasting glucose compared to non-cases among blacks (42.9 
vs. 19.6%, p<0.001) and Asians (median 22.5 vs. 13.4%, p<0.01), and less so among whites 
(27.9 vs. 22.9%, p<0.01), but there was no significant difference among Hispanics (20.6 vs. 
19.3%, p=0.44) (Figure 4-3, p-heterogeneity=0.01). Additionally, the percent differences in 
HbA1c was doubled for cases compared to non-cases among whites (median 11.5 vs. 5.2%, 
p<0.001) and blacks (12.9 vs. 5.0%, p<0.01), but was not significant for other race/ethnicity 
groups (Figure 4-3, p-heterogeneity<0.0001). Finally, the difference in the percent weight lost 
between cases and non-cases was significant among whites (-3.7 vs. 0.0%, p<0.0001) and Asians 
(-2.0 vs. 0.2%, p<0.01), but not among blacks (-0.5 vs 0.0%, p=0.08) or Hispanics (0.0 vs. 0.1%, 
p=0.08) (Figure 4-3, p-heterogeneity<0.001). 
For pancreatic cancer risk, each 10% unit increase in the percent difference of fasting 
glucose was associated with a 4% greater risk (RR 1.04, 95% CI 1.03-1.05), while each unit 
increase in the rate of change was associated with a 6% elevated risk (RR 1.06, 95% CI 1.04-
1.07). These associations were similar across race/ethnicity, but were stronger among Asians 
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(percent difference: RR 1.12, 95% CI 1.06-1.17, p-heterogeneity=0.02; rate of change: RR 1.13, 
95% CI 1.07-1.19, p-heterogeneity=0.06; Table 4-5). Moreover, each unit increase in the percent 
difference in HbA1c was associated with a 2% elevated risk (RR 1.02, 95% CI 1.02-1.03) and 
each 0.1%/month increase in the rate of change had a 45% increased risk (RR 1.45, 95% CI 
1.26-1.66). For weight, each 3% unit decrease in the percent difference had a 24% increased risk 
(RR 1.24, 95% CI 1.18-1.31) and each unit decrease in the rate of change had a 62% increase 
(RR 1.62, 95% CI 1.44-1.82) in pancreatic cancer risk. The impact of the percent difference in 
weight on pancreatic cancer risk was more pronounced among whites (RR 1.32, 95% CI 1.24-
1.40) and Asians (RR 1.22, 95% 1.03-1.45) than among Hispanics (RR 1.14, 95% 1.01-1.29) and 
blacks (RR 1.07, 95% CI 0.92-1.26, p-heterogeneity=0.02) (Table 4-5). 
  
4.3 Discussion  
 In this study, we evaluated the influence of diabetes status, diabetes duration and 
metabolic profiles on pancreatic cancer risk within a large and diverse population-based cohort. 
We observed that patients with incident and prevalent diabetes had three and two times the risk, 
respectively, of pancreatic cancer compared with patients without diabetes. In addition, this risk 
was elevated nearly seven times for incident diabetes patients with ≤1 year of disease duration 
and about two times for incident diabetes patients with >1 year disease duration. Among incident 
diabetes patients, those who went on to develop pancreatic cancer had greater increases in fasting 
glucose, HbA1c and weight loss in the time leading up to diabetes diagnosis. The longitudinal 
changes in metabolic characteristics between cases and non-cases also appeared to differ by 
race/ethnicity. 
Prior epidemiologic studies have found that diabetes is associated with a two times higher 
risk of pancreatic cancer, with higher risks observed for those with shorter durations of 
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diabetes25,54. Our main findings are generally consistent with past research, as both incident and 
prevalent diabetes patients had around a two to three times greater risk compared to non-diabetes 
patients. The elevated risk among incident diabetes patients was driven primarily by the seven-
fold increased risk for those who had diabetes for ≤1 year, while those with longer disease 
durations had risks resembling that of prevalent diabetes patients. These results add support for 
the hypothesis that pancreatic cancer patients with diabetes for shorter periods may actually have 
a distinct form of diabetes that is induced by the pancreatic tumor51,52.  
Importantly, we observed that these patterns of association were similar across all 
race/ethnicity subgroups. Most of the prior literature on diabetes duration has been focused on 
white populations and only a sparse number of studies have examined this relationship among 
minorities60,113,114. Despite this, our results are congruent with previous research showing that 
shorter durations of diabetes are also associated with higher pancreatic cancer risk among non-
whites. To our knowledge, this is the first population-based cohort study to evaluate multiple 
race/ethnicity groups together with sufficient pancreatic cancer cases within each race/ethnicity 
to power analyses to detect a range of associations.  
In our metabolic profiling of incident diabetes patients, we found that pancreatic cancer 
cases had similar levels of fasting glucose and HbA1c in the period before diabetes, but higher 
levels at diabetes diagnosis, compared to non-cases. However, weight was significantly lower for 
pancreatic cancer patients in both time windows, indicating that changes in weight may occur 
earlier in the pathogenesis of pancreatic cancer. These patterns are fairly similar to findings from 
earlier studies of new-onset diabetes patients, which found lower weight and higher blood 
glucose and HbA1c at diabetes diagnosis among those who ultimately developed pancreatic 
cancer115,116.  
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Moreover, pancreatic cancer patients had higher percent increases of glucose, HbA1c and 
weight loss in the time leading up to diabetes diagnosis. Of multiple metabolic changes, percent 
differences in fasting glucose seemed to show the most variability by race/ethnicity; Asians and 
blacks had the biggest deviations between cases and non-cases, while whites had smaller 
variations and Hispanics had no significant difference. While there appeared to be dissimilarities 
for HbA1c by race/ethnicity, these results are based on a smaller group of patients, as there were 
few pancreatic cancer cases with at least two HbA1c measurements. Weight loss had the least 
fluctuations across race/ethnicity, with percent decreases of 1-4% for cases and very little change 
among non-cases. This indicates that weight loss is a more consistent biomarker of pancreatic 
carcinogenesis across race/ethnicity5. Of note, none of the percent differences in glucose, HbA1c 
or weight between cases and non-cases were statistically significant among Hispanics, 
suggesting that pancreatic cancer may have less of an influence on these metabolic markers in 
this population. 
Higher percent differences and rates of change for fasting glucose, HbA1c and weight 
were all significantly associated with pancreatic cancer in our multivariate modeling. These 
metabolic changes have also been associated with pancreatic cancer in past studies of new-onset 
diabetes117–119 and have been identified as significant parameters in recent risk prediction 
models115,116. In particular, the Enriching New-onset Diabetes for Pancreatic Cancer model from 
the Mayo Clinic reported that increases in blood glucose and weight loss by diabetes diagnosis 
were predictive markers of pancreatic cancer risk116. Additionally, the model developed in The 
Health Improvement Network in the United Kingdom found that higher levels of HbA1c and 
larger decreases in BMI at diabetes diagnosis were also significant predictors of pancreatic 
malignancy115. As these previous studies were all conducted in mainly white populations, our 
study is the first to show that these metabolic changes can also be used to determine risk in 
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heterogeneous populations with different lifestyles and genetic susceptibilities. The general 
consistency in findings for higher risk of pancreatic cancer associated with recent-onset diabetes 
across multiple racial/ethnic groups suggests that prediction models developed in predominantly 
white individuals115,116 would apply broadly to minority populations in the U.S. 
 The major strengths of this study include the diverse patient population and the largest 
number of pancreatic cancer cases among all past cohort studies, which make our findings more 
robust and generalizable. Establishing a cohort from members of an integrated health system 
further assured that individuals had similar healthcare access and were less likely to be lost to 
follow-up. We also had more reliable and complete data by using the prospectively collected 
electronic health records. In particular, using glucose and HbA1c tests for both exclusion criteria 
and case ascertainment controlled for healthcare utilization and improved the accuracy of 
identifying diabetes patients, respectively. However, only a proportion of patients had more than 
one glucose or HbA1c measurement, so our findings for metabolic changes are based on a subset 
of patients that have more clinic visits, which could include a spectrum of patients from healthy 
individuals compliant with annual physicals to individuals with greater disease burden that 
necessitates more frequent patient-provider encounters. In addition, the varying lengths of time 
between the two metabolic measurements across patients could have influenced the results 
comparing percent differences between cases and non-cases. Nonetheless, a majority of the 
patients had less than one year between their two measurements and the results for the percent 
differences were consistent with those for the rates of change for all metabolic markers. Lastly, 
we did not have much information on systemic insulin levels, another potential important 
metabolic biomarker120, as this lab test is not frequently ordered by KPSC providers. Ultimately, 
data from electronic health records are not as detailed and complete as epidemiologic 
questionnaires for certain exposures, such as smoking and alcohol use.  
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 In this population-based cohort study, we illustrate that the elevated pancreatic cancer 
risk associated with new-onset diabetes is also present among multiple racial/ethnic minorities. 
Additionally, the metabolic profiles of these incident diabetes patients appear to vary across 
race/ethnicity, suggesting that certain biomarkers could have more clinical relevance or utility 
for specific populations. These findings offer more insight into the complex diabetes-pancreatic 
cancer relationship and may help guide decisions towards tailoring prevention techniques and 
methods for identifying patients most appropriate for screening.  
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CHAPTER 5. SPECIFIC AIM 3 – METHYLATION OF CYTOKINE GENES 
 
5.1 Methods 
5.1.1 Study Population 
 We performed a retrospective cohort study of pancreatic cancer patients from The Cancer 
Genome Atlas (TCGA). TCGA is a large-scale collaboration between the National Cancer 
Institute (NCI) and National Human Research Institute (NHGRI) that provides complete 
genomic sequencing and epigenetic data on 11,000 patients across 33 different tumor types. It 
involves the participation of twenty institutions across the United States and Canada and includes 
clinical data and comprehensive genomic profiling of both tumor and matched normal tissues121. 
For this study, we included all patients with a primary pancreatic cancer tumor sample. Since this 
patient sample was primarily white (88%), we excluded all non-white individuals from the 
analysis. All de-identified data was downloaded from TCGA using the TCGAbiolinks package in 
R122.  
   
5.1.2 Methylation Values 
DNA methylation profiles of TCGA pancreatic cancer samples were obtained using the 
Illumina Infinium HumanMethylation450 (HM450) BeadChip methylation assay123,124. This 
assay measures the methylated and unmethylated signal intensities of over 450,000 CpG 
dinucleotide sites across the genome, which are enriched for regulatory elements and promoter 
regions125. Raw methylation intensities downloaded from TCGA were pre-processed using 
normal-exponential out-of-band (noob) background correction with dye-bias normalization and 
converted to beta-values with the minfi package123,126. Beta-values were calculated from the 
corrected methylated (ms) and unmethylated (mu) signal intensities using the formula 
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β=ms/(ms+mu) and range from 0 to 1, with larger values indicating higher levels of 
methylation123. 
We filtered CpG probes by dropping those that overlapped with single nucleotide 
polymorphisms (SNPs) with minor allele frequency of 5% based on the CEU population127. 
These SNPs can interfere with probe binding, as well as influence methylation signal intensities 
since the HM450 assay can erroneously detect the common C to T polymorphism as a change in 
methylation125,128. We also dropped loci that had poor hybridization using the updated 
characterization file for the HM450 assay developed by Zhou et al129.  
As a sensitivity analysis, we performed additional pre-processing and calculated beta-
values using the newly developed SeSAMe pipeline, which uses the P-value with out-of band 
array hybridization (pOOBAH) method to further adjust for poorly performing probes with failed 
hybridization130.  
 
5.1.3 CpG Probe Selection 
We conducted a candidate gene approach, focusing on CpG loci in proximity to genes 
coding for cytokines that have been associated with pancreatic cancer survival in previous 
studies: IL10, IL6, IL8, TGFβ1, TGFβ2, TGFβ3, and TNF. Using the annotation file from the 
HM450 assay, we identified 113 total CpG loci across these seven genes. One probe in TGFB2 
was dropped due to failed hybridization and one probe in TGFB3 was dropped due to SNP 
overlap, leaving a total of 111 CpG loci (6 for IL10, 11 for IL6, 2 for IL8, 25 for TGFβ1, 23 for 
TGFβ2, 16 for TGFβ3 and 28 for TNF). 
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5.1.4 Assessment of Genetic Regulation and Expression 
Genetic regulatory elements associated with the selected CpG loci were determined using 
the core 15-state model of chromatin states for the pancreas tissue epigenome developed by the 
NIH Roadmap Epigenomics Mapping Consortium131. The core 15-state model was created with 
ChromHMM, which establishes chromatin state signatures using multivariate Hidden Markov 
Models132 and indicates whether the genetic region is associated with regulatory elements, such 
as active transcription start sites (TSS), weak transcription, enhancers, and heterochromatin131. 
Chromatin states were mapped to the CpG loci using the GenomicRanges package133. 
To evaluate whether the methylation sites were associated with changes in gene 
expression, we also downloaded Level 3 mRNA expression data from TCGA. Raw expression 
reads were evaluated with RESM and standardized using the upper-quartile normalization 
approach134. 
 
5.1.5 Assessment of Other Variables 
 Data on smoking, alcohol, tumor characteristics (e.g. stage) and treatment (e.g. radiation 
therapy), death, and last day of follow-up were obtained from the TCGA clinical files.  
 
5.1.6 Statistical Analyses 
We evaluated methylation at three levels of analysis: at the level of the individual CpG 
locus, at the level of each chromatin state per gene, and at the level of the entire gene. For the 
chromatin state- and gene-level analyses, we used the average methylation across all CpG loci in 
the given region as the exposure. For all units of analysis, the relationship between methylation 
and expression of its respective gene was assessed by calculating the Spearman’s correlation 
coefficient (r). We used Cox proportional hazards regression to assess the relationship between 
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methylation and pancreatic cancer survival. Individuals were followed from time of diagnosis 
and censored at death or date of last contact. There was one tied event time, which was handled 
by calculating the exact likelihood. Methylation beta-values were rescaled to model each 0.01 
increase in the mean beta value.  
We used independent surrogate variable analysis (ISVA) to identify potential batch 
effects and measurement error in confounders that may bias results128,135. In this step, the residual 
variation in DNA methylation across the array that was not associated with time to death or last 
contact was first decomposed into independent components. Next, independent surrogate 
variables (ISVs) were constructed from the independent components that were significantly 
associated (using an alpha level of 0.05) with our confounders of interest: age (continuous), 
gender (male vs. female), stage (I, II, III/IV), smoking (never, former, current), receipt of 
radiation therapy (yes vs. no), and sample plate. Since we planned to adjust for age, gender, and 
stage in all fully adjusted models, we selected the ISVs that were significantly associated with 
any of the remaining potential confounders (smoking, receipt of radiation, or sample plate) as 
covariates in our models. ISVA identified seven total independent surrogate variables, five of 
which were included in our final models.  
For each unit of analysis (CpG locus, chromatin state, or gene), we ran one model 
minimally adjusted for age and gender, and a fully adjusted model with age, gender, stage and 
the five ISVs as covariates. To evaluate the impact of probes with failed hybridization, we 
repeated all analyses using the beta-values pre-processed by the SeSAMe pipeline. As there were 
no differences in the results for two beta-value datasets, only the results from the noob-processed 
dataset are presented. 
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For the chromatin state- and gene-level analyses, we performed additional subgroup 
analyses stratified by gender and smoking (ever vs. never). Heterogeneity was assessed using a 
separate model with a product term for methylation and the stratifying variable.  
Schoenfeld residuals were used to confirm no violation of the proportional hazards 
assumption. Martingale residuals, deviance residuals, and delta-beta values were reviewed to 
examine model fit. Wald tests with an alpha level of 0.05 were used to determine significance. 
All analysis was performed in R version 3.5.1. 
 
5.2 Results 
Our sample included 162 pancreatic cancer cases with primary tumor samples in the 
TCGA database (Table 5-1). The cohort consisted of 70 females (43.2%) and 92 males (56.8%) 
and the mean age of pancreatic cancer diagnosis was 65.5 years (standard deviation 10.7 years). 
Over 90% of patients had tumors of early stage (Stage I/II). There were 57 (35.2%) deaths by the 
end of follow up (Table 5-1). Samples were spread across twelve different plates in the 
methylation assay. 
The 111 CpG probes of interest were associated with a variety of chromatin states in 
pancreas tissue. Flanking active TSS (27.9%) were the most common, followed by quiescent/low 
(26.1%), weak transcription (19.8%), active TSS (17.1%), enhancers (7.2%), strong transcription 
(0.9%) and weak repressed polycomb (0.9%). 
Increased DNA methylation at several loci in TGFβ1, TGFβ2 and TGFβ3 was 
significantly associated with poor pancreatic cancer survival in the models fully adjusted for age, 
gender, stage and the five surrogate variables. Each 0.01 increase in DNA methylation beta-value 
at cg03313751 and cg24767336, both located in proximity to the TGFβ1 TSS, was associated 
with a 62% (HR 1.62, 95% CI 1.14-2.31) and 46% (HR 1.46, 95% CI 1.06-2.02) elevated hazard 
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of pancreatic cancer death, respectively (Table 5-2, Figure 5-1). Methylation at these sites also 
had a weak to moderate negative correlation with TGFβ1 expression (cg03313751: Spearman’s 
r=-0.295, p<0.001; cg24767336: r=-0.223, p=0.005). A 0.01 increase in beta-value was 
associated with a borderline increased hazard of death for cg11037750 (HR 1.02, 95% CI 1.00-
1.05) and cg09926389 (HR 1.02, 95% CI 1.00-1.03) within the TGFβ1 gene body. Methylation 
at both of these CpG loci had a moderate positive correlation with TGFβ1 expression 
(cg11037750: r=0.506, p<0.001; cg09926389: r=0.438, p<0.001).  
For cg16658719 and cg16361301, both located near the TGFβ2 TSS, each 0.01 increase 
in beta-value was associated with a 58% (HR 1.58, 95% CI 1.21-2.06) and 19% (HR 1.19, 95% 
CI 1.00-1.41) higher hazard of mortality, respectively. However, methylation was not correlated 
with TGFβ2 expression at either locus (Table 5-2, Figure 5-2). Increased methylation at two 
additional loci within the TGFβ2 gene body (cg20698667, cg16967578) were associated with a 
slight (2-5%) increased hazard of mortality (Table 5-2, Figure 5-2). In addition, methylation at 
cg20698667 had a weak negative correlation with TGFβ2 expression (r=-0.174, p=0.030).  
For TGFβ3, each 0.01 increase in the methylation beta-value at cg16292972, located near 
the TGFβ3 TSS, was associated with a 45% elevated hazard of mortality (HR 1.45, 95% CI 1.01-
2.09). However, methylation at this probe was not correlated with TGFβ3 expression (r=0.066, 
p=0.414, Figure 5-3). Higher methylation at three other probes on TGFβ3 (cg13121428, 
cg24696715, cg18298494) was associated with improved survival in the models minimally 
adjusted for age and gender, but were no longer significant after adjusting for all covariates 
(Table 5-2). All of these loci had a moderate inverse correlation with expression (cg13121428: 
r=-0.415, p<0.001; cg24696715: r=-0.466, p<0.001; cg18298494: r=-0.282, p<0.001). 
In TNF, increased methylation at seven CpG sites, all associated with either weak 
transcription or quiescent/low chromatin states, were associated with a modest increased hazard 
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of death (3-5%) in the models minimally adjusted for age and gender (Table 5-2). All of these 
CpG loci were no longer significant after adjusting for the remaining covariates. Only 
cg09637172, located in the gene body, had a borderline increased hazard of death in the fully 
adjusted models (HR 1.03, 95% CI 1.00-1.07). Methylation at cg09637172 also had a moderate 
negative correlation with TNF expression (r=-0.397, p<0.001).  
Elevated methylation in two CpG loci located in proximity to the IL6 TSS were 
associated with mortality in the fully adjusted models. Each 0.01 increase in beta-value was 
associated with a borderline 2% higher hazard of death in cg00087425 (HR 1.02, 95% CI 1.00-
1.04) and a 3% higher hazard of mortality in cg15703690 (HR 1.03, 95% CI 1.00-1.05). There 
was no correlation between methylation and IL6 expression for either of these CpG loci (Table 
5-2, Figure 5-4).  
Conversely, higher methylation in cg14789529, located near the IL10 three prime 
untranslated region (3’ UTR), was associated with a decreased hazard of death (HR 0.97, 95% CI 
0.94-1.00). There was also a weak inverse correlation between methylation at this CpG locus and 
IL10 expression (r=-0.253, p=<0.001, Figure 5-5). For the remaining five IL10 probes, all 
associated with quiescent/low chromatin states, methylation was not associated with mortality. In 
addition, none of the probes on IL8 were associated with pancreatic cancer survival (Table 5-3).  
When evaluating the average methylation levels across chromatin states, we observed 
higher hazards of death for higher methylation levels in quiescent/low chromatin states in IL6 
(HR 1.04, 95% CI 1.00-1.07), weak transcription in TGFβ1 (HR 1.06, 95% CI 1.01-1.10), and 
weak transcription in TNF (HR 1.07, 95% 1.02, 1.13) in the minimally adjusted models. 
However, none of these associations remained significant after adjusting for all covariates. For 
average methylation across entire genes, higher methylation in TGFβ1 was associated with an 
elevated hazard of death in the minimally adjusted model (HR 1.16, 95% 1.01-1.33), but not in 
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the fully adjusted model (HR 1.11, 95% 0.93-1.32). Higher average methylation in TGFβ1 had a 
moderate positive correlation with expression (r=0.330, p<0.001) (Table 5-4). 
In the subgroup analyses, higher methylation in IL6 was associated with an increased 
hazard of death among never smokers (HR 1.14, 95% 1.01-1.29), but not among ever smokers 
(HR 0.97, 95% CI 0.88-1.07, p-interaction=0.05). This association was driven mainly by the 
methylation across the three CpG loci in the enhancer region of IL6, which was associated with a 
greater hazard of death in never smokers (HR 1.17, 95% CI 1.02-1.34) and a borderline 
decreased hazard of death in ever smokers (HR 0.88, 95% CI 0.77-1.00, p-interaction=0.001). 
There was no other significant interaction by smoking status for methylation in any of the other 
genes and chromatin states. In addition, we did not observe any heterogeneity by gender for any 
chromatin state- or gene-level analyses. 
 
5.3 Discussion 
 In this study, we examined the associations between DNA methylation in proximity to 
cytokine-related genes and survival among pancreatic cancer patients from The Cancer Genome 
Atlas. Increased methylation in several CpG probes in TGFβ1, TGFβ2 and TGFβ3 was 
significantly associated with lower survival, with the highest hazard of death found among CpG 
loci located near transcription start sites. Elevated methylation in two CpG loci in IL6 was 
associated with a modest increase in pancreatic cancer mortality rates while higher methylation 
in one CpG locus in IL10 appeared to have a protective association. 
TGF-β is an immunosuppressive cytokine that has been found to be directly secreted by 
pancreatic cancer tumor cells62. Past literature has shown that higher serum concentrations of 
TGF-β are associated with lower pancreatic cancer survival74,78,136. In our study, we observed 
that higher methylation in multiple loci across TGFβ1, TGFβ2 and TGFβ3 was associated with 
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increased hazards of mortality. DNA methylation in TGF-β genes and pancreatic cancer survival 
have been evaluated in two previous studies, which actually found longer survival among 
individuals with greater methylation in TGFβ291,92. Both of these studies, however, had patient 
samples and methods that were dissimilar from the present analysis. In the first study, which 
used a subset of TCGA pancreatic tumor samples, the authors evaluated overall TGFβ2 gene 
methylation and separated individuals into short (<1 year) and long (>2 year) survival groups92. 
In the other study, the researchers found that higher methylation in one CpG site in TGFβ2 was 
associated with improved survival, but the results were not fully adjusted and were only based on 
a small sample of eleven pancreatic cancer tumors91. Given these differences in study design, 
future research with more consistent methods are needed to validate the current findings.  
Among the TGFβ1, TGFβ2 and TGFβ3 CpG sites that were associated with mortality in 
our study, the strongest associations were observed among loci located near transcription start 
sites. However, the methylation of the CpG loci in proximity to the transcription start sites had 
weak to moderate correlation with expression in their respective genes. One possible explanation 
for this scenario could be that methylation at these particular CpG sites may not account for all 
epigenetic regulation of gene expression. Additionally, there has been limited literature on the 
association between TGF-β gene expression and pancreatic cancer mortality. The only previous 
study examining this relationship, also using TCGA data, found enhanced survival among 
patients with TGFβ1 overexpression79. 
TNF-α is a pro-inflammatory cytokine that has been observed to be involved in the 
progression and invasiveness of pancreatic tumors70,137. Past literature has shown that pancreatic 
cancer patients have higher levels of both TNF expression and serum TNF-α concentrations 
compared to controls69,138. In our study, higher methylation in a few CpG loci in TNF was 
associated with shorter survival in the minimally adjusted models, but not in the fully adjusted 
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models. Previous DNA methylation studies on TNF are sparse and have focused on genes in the 
TNF receptor superfamily, which observed higher methylation in TNFRSF1A in the leukocyte 
DNA of pancreatic cancer patients139 and lower methylation for TNFRSF10C in pancreatic 
cancer cell lines140. Research on TNF expression and pancreatic cancer mortality has also been 
somewhat inconsistent. While two prior studies found no relationship between TNF expression 
and mortality71,141, another study found that increased expression was associated with decreased 
survival75. To our knowledge, this is the first study to evaluate DNA methylation in TNF and 
survival in pancreatic cancer patients.   
IL-6 is a pleiotropic cytokine that is involved in several pathways in pancreatic cancer 
tumorigenesis142,143. Many prior studies have found poorer survival among pancreatic cancer 
patients with higher serum levels of IL-671,74,77,80. In our analysis, we detected modest increased 
risks for mortality with increased methylation at two CpG loci in IL6. The relationship between 
DNA methylation in IL6 and pancreatic cancer has not been well evaluated in current literature. 
While a previous study observed lower leukocyte DNA methylation in IL6 among pancreatic 
cancer patients139, no prior study has evaluated DNA methylation in this gene in the context of 
pancreatic cancer survival. In addition, both of these CpG sites were located near the IL6 TSS, 
but there was no significant correlation between methylation and IL6 expression. It is possible 
that DNA methylation in this region does not have a strong influence on genetic expression. 
IL-10 is an anti-inflammatory cytokine that is released by pancreatic cancer cells and 
contributes to the development of a tumor-tolerating microenvironment70,137. Current evidence 
has suggested that higher concentrations of IL-10 is associated with poorer survival in pancreatic 
cancer patients71,77. We found that increased methylation in one CpG site in IL10, which was not 
correlated with expression, had a protective association with mortality. Though there has been no 
other literature on IL10 DNA methylation and survival, previous studies have found lower IL10 
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methylation in leukocyte DNA139 and increased IL10 expression74 in the tumor tissue among 
pancreatic cancer cases. In addition, IL10 has been shown to be hypomethylated in other 
malignancies, such as colon, kidney, stomach, lung, breast cancer144. 
A major strength of this study is that it is one of the larger cohorts to evaluate DNA 
methylation in proximity to cytokine genes and pancreatic cancer survival using a candidate gene 
approach. Past research on this topic has been evaluated primarily in epigenome-wide 
association studies with much smaller samples size. We also incorporated chromatin states and 
expression in our analyses, which enhanced the interpretability of our results. However, our 
sample size was not sufficiently powered to perform subgroup analyses, so we do not know if the 
observed associations differ by certain patient characteristics. Generalizability of our results may 
also be an issue since the patient population was comprised of only white individuals with early-
stage tumors. However, the age and sex distributions of the cohort are fairly similar to observed 
rates among pancreatic cancer patients in the United States145. Furthermore, the pancreatic tissue 
samples may likely be within a mixture of other cells that could have impacted some of the 
associations. As the pancreatic cancer tumor microenvironment involves the interaction of many 
different cell types, we did not adjust for cellular heterogeneity because it could have perhaps 
overcorrected and removed true biologic signals. 
Each cytokine gene in this study was selected specifically because increased expression 
or serum concentrations of the cytokine was associated with pancreatic cancer in prior literature. 
Thus, we treated each gene as a unique hypothesis and did not perform correction for multiple 
testing. However, if we were to apply the Benjamini and Hochberg procedure to control the false 
discovery rate at a q-level of 0.05 in each gene146, only cg16658719 in TGFB2 would still be 
considered significant. On the other hand, several loci in the minimally adjusted models would 
still meet the corrected threshold for significance, indicating a potential loss of statistical power 
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when adjusting for additional covariates. Ultimately, our observed findings are still helpful for 
describing associations and generating hypotheses on the relationship between the immune 
system and pancreatic carcinogenesis.  
 In this study of pancreatic cancer patients from TCGA, we report reduced survival for 
higher methylation in CpG sites across TGFB1, TGFB2, TGFB3, and IL6 and improved survival 
for higher methylation in one CpG locus in IL10. Our findings suggest that the interactions 
between cytokines and pancreatic cancer progression may potentially be influenced by 
epigenetic modifications. As epigenetics research on cytokine-related genes and pancreatic 
cancer is still quite sparse, future studies should evaluate these associations in larger samples to 
further elucidate the immune-associated mechanisms behind pancreatic cancer development and 
mortality.   
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CHAPTER 6. CONCLUSIONS AND PUBLIC HEALTH IMPLICATIONS 
 
In this study, we investigated the relationships between several immune- or 
inflammation-related exposures and pancreatic cancer risk and survival. In Aim 1 using data 
from the prospective Multiethnic Cohort, we conducted the first study examining the association 
between AACs and antihistamines with pancreatic cancer in a diverse and well-powered 
prospective setting. Our results are consistent with that of past prospective studies and provide 
additional support of a null association for overall AACs. In Aim 2 utilizing hospital-based 
records from Kaiser Permanente Southern California, we found that the elevated pancreatic 
cancer risk associated with new-onset diabetes is also present among multiple racial/ethnic 
minorities. Additionally, the metabolic profiles of these incident diabetes patients appear to vary 
across race/ethnicity. Finally, in Aim 3 evaluating pancreatic cancer patients from The Cancer 
Genome Atlas, we detected reduced survival for higher methylation in CpG sites across TGFB1, 
TGFB2, TGFB3, IL6 and enhanced survival for higher methylation in one CpG locus in IL10.  
These findings provide further evidence of the complex interaction of the immune system 
and pancreatic cancer. While overall allergies may not be a reliable indicator for risk, utilizing 
markers of metabolic disorder could potentially be more effective at identifying high risk 
individuals. Specifically, the interethnic variations in metabolic changes prior to pancreatic 
cancer suggest that certain biomarkers could have more clinical relevance or utility for specific 
populations. Lastly, the outcomes from our methylation analysis indicate that the epigenetic 
alterations of immune activity may be involved in pancreatic carcinogenesis and survival.  
Elucidating these immune-related mechanisms may support not only the tailoring of 
prevention and screening techniques, but also the enhancement of current immunotherapy-based 
therapies. By further understanding the associations between allergies and diabetes on pancreatic 
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cancer risk, clinicians can better define patient populations that are most appropriate for 
screening. In particular, our results for diabetes onset and metabolic markers may have 
significant implications for clinical practice by providing further opportunities for early 
detection. Moreover, our epigenetic findings may promote the development of targeted 
treatments with new methylation- and/or immune-based markers. Together, these results can be 
incorporated into the refinement of risk and survival prediction models that will allow patients to 
better understand their disease risk and prognoses, ultimately helping to control and reduce the 
burden of this lethal malignancy.  
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TABLES 
Table 1-1. Cytokines and their relationship with pancreatic cancer survival 
 
Cytokine Function70,71 Association with survival* 
Anti-inflammatory 
IL-10 • Inhibit Th1 responses, promote Th2 responses Decreased survival71,77 
TGF-β • Inhibit Th1 responses, promote Th2 responses Decreased survival74,75,78 
Increased survival79 
   
Pro-inflammatory 
IL-6 • Stimulates angiogenesis and tumor vascularization 
• Interacts with IL-10 and TGF-β to inhibit dendritic cell proliferation 
Decreased survival71,74 
IL-8 • Promotion of angiogenesis 
• Activates MAPK pathway which stimulates cell growth 
• Promotes tumor aggressiveness and invasiveness 
Decreased survival72 
No association71  
TNF-α • Promotes cancer proliferation 
• Increases tumor invasiveness 
Decreased survival72,75 
Increased survival80 
*For higher concentrations or expression of cytokine 
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Table 3-1. Baseline characteristics of Multiethnic Cohort Study participants from 1993-
2012, stratified by atopic allergic conditions (AAC) status 
 
 
Total 
(N=187,226) 
No AACs 
(N=137,530) 
AACs 
(N=49,696)  
Characteristic N % N % N % p1 
Pancreatic cancer cases 1,455 0.8 1,094 0.8 361 0.7  
Follow-up time (years)2 16.2 (4.7) 16.1 (4.8) 16.5 (4.5)  
Pancreatic cancer incidence rate3 49.0  50.2  44.8   
Age at baseline (years)2 59.9  (8.8) 60.2  (8.8) 58.8  (8.9) <0.0001 
Age group at baseline (years)       <0.0001 
<50 31,454 16.8 21,439 15.6 10,015 20.2  
 50-54 28,050 15.0 19,853 14.4 8,197 16.5  
 55-59 29,875 16.0 21,830 15.9 8,045 16.2  
 60-64 32,245 17.2 24,068 17.5 8,177 16.5  
 65-69 32,885 17.6 25,093 18.2 7,792 15.7  
 70+ 32,717 17.5 25,247 18.4 7,470 15.0  
Sex       <0.0001 
Male 85,381 45.6 67,962 49.4 17,419 35.1  
Female 10,1845 54.4 69,568 50.6 32,277 64.9  
Ethnicity       <0.0001 
White 46,858 25.0 32,245 23.4 14,613 29.4  
African American 31,500 16.8 23,252 16.9 8,248 16.6  
Latino 41,547 22.2 32,876 23.9 8,671 17.4  
Japanese American 53,746 28.7 39,484 28.7 14,262 28.7  
Native Hawaiian 13,575 7.3 9,673 7.0 3,902 7.9  
Family history of pancreatic 
cancer 3,193 1.7 2,197 1.6 996 2.0 <0.0001 
Diabetes 21,997 11.7 16,773 12.2 5,224 10.5 <0.0001 
Body mass index (kg/m2)       <0.0001 
<25 77,887 41.6 56,562 41.1 21,325 42.9  
25-30 71,887 38.4 54,141 39.4 17,746 35.7  
≥30 37,452 20.0 26,827 19.5 10,625 21.4  
Smoking status       <0.0001 
Never 82,113 43.9 59,630 43.4 22,483 45.2  
Past 75,100 40.1 54,685 39.8 20,415 41.1  
Current 30,013 16.0 23,215 16.9 6,798 13.7  
Education       <0.0001 
≤12 years 81,972 43.8 64,784 47.1 17,188 34.6  
Some college/vocational 55,406 29.6 39,211 28.5 16,195 32.6  
College graduate 49,848 26.6 33,535 24.4 16,313 32.8  
Alcohol intake (g/day)4       <0.0001 
None 95,609 51.1 69,742 50.7 25,867 52.1  
<24 g 70,227 37.5 51,509 37.5 18,718 37.7  
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24-48 g 13,351 7.1 10,069 7.3 3,282 6.6  
>48 g 8,039 4.3 6,210 4.5 1,829 3.7   
Ever use of antihistamines 28,413 15.2 8,381 6.1 20,032 40.3 <0.0001 
Allergy severity       <0.0001 
None 137,530 73.5 137,530 100.0 0 0.0  
AACs with no medication use 28,089 15.0 0 0.0 28,089 56.5  
AACs with medication use 20,032 10.7 0 0.0 20,032 40.3  
Abbreviations: AAC, atopic allergic condition; SD, standard deviation 
1From a t-test for age and chi-square test for all other variables 
2Mean (SD)  
3Incidence rate per 100,000 person-years, age-standardized to US Census 2000 standard population, left truncated at 
age 45 
4Intake during the year prior to cohort entry 
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Table 3-2. Associations between various allergy-related exposures and pancreatic cancer 
 
Exposure N Cases 
Minimally adjusted 
RR (95% CI)1 
Fully adjusted  
RR (95% CI)2 
Atopic allergic conditions (AACs)     
No 137,530 1,094 1 (ref) 1 (ref) 
Yes 49,696 361 0.97 (0.86-1.10) 1.00 (0.88-1.12) 
Ever use of antihistamines3     
No 149,760 1,191 1 (ref) 1 (ref) 
Yes 28,413 190 0.90 (0.77-1.05) 0.92 (0.78-1.07) 
Duration of antihistamine use4     
None 149,760 1,191 1 (ref) 1 (ref) 
≤5 years of medication use 15,405 92 0.81 (0.65-1.00) 0.82 (0.66-1.01) 
>5 years of medication use 9,538 76 1.09 (0.86-1.37) 1.12 (0.89-1.42) 
ptrend5   0.71 0.94 
Allergy severity     
None 137,530 1,094 1 (ref) 1 (ref) 
AACs with no medication use 28,089 208 0.99 (0.85-1.15) 1.01 (0.87-1.17) 
AACs with medication use 20,032 142 0.96 (0.81-1.15) 0.99 (0.83-1.19) 
ptrend5   0.67 0.98 
1Adjusted for age, sex, ethnicity 
2Adjusted for age, sex, ethnicity, education, smoking status, family history of pancreatic cancer, 
education, BMI, diabetes, and alcohol intake.  
3Information on antihistamine use missing for 9,053 participants (4.8% of cohort) 
4Length of antihistamine use missing for 3,470 participants (12.2% of medication users) 
5From a model treating exposure as a continuous variable
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Table 3-3. Association between atopic allergic conditions and pancreatic cancer among 
subgroups of cohort 
 
Subgroup Non-AAC Cases AAC Cases RR (95% CI)1 p 
All 1094 361 1.00 (0.88-1.12) 0.94 
     
Age group at baseline    0.202 
<50 69 35 1.15 (0.76-1.74) 0.50 
50-54 86 34 1.03 (0.69-1.54) 0.88 
55-59 146 66 1.29 (0.96-1.74) 0.09 
60-64 185 63 0.99 (0.74-1.32) 0.94 
65-69 314 100 1.00 (0.80-1.26) 0.98 
70+ 294 63 0.74 (0.56-0.98) 0.03 
     
Sex    0.912 
Male 555 133 1.01 (0.83-1.22) 0.95 
Female 539 228 0.99 (0.84-1.15) 0.85 
     
Ethnicity    0.522 
Whites 209 83 0.95 (0.73-1.23) 0.70 
African Americans 216 68 0.92 (0.70-1.21) 0.54 
Latinos 200 58 1.16 (0.86-1.56) 0.33 
Japanese Americans 376 126 1.06 (0.86-1.30) 0.58 
Native Hawaiians 93 26 0.78 (0.50-1.22) 0.28 
     
Follow-up time (years)    0.272 
<5 211 54 0.76 (0.56-1.04) 0.08 
≥5 883 307 1.04 (0.91-1.18) 0.59 
     
Family history of 
pancreatic cancer    0.132 
No 1055 351 1.01 (0.90-1.15) 0.85 
Yes 39 10 0.61 (0.30-1.23) 0.17 
     
Diabetes    0.742 
No 929 310 0.99 (0.87-1.13) 0.85 
Yes 165 51 1.04 (0.75-1.43) 0.82 
     
Body mass index (kg/m2)    0.192 
<25 453 134 0.88 (0.72-1.07) 0.19 
25-30 426 139 1.06 (0.87-1.28) 0.58 
≥30 215 88 1.13 (0.88-1.46) 0.33 
     
Smoking status    0.492 
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Never 461 168 1.07 (0.89-1.28) 0.49 
Past 424 133 0.89 (0.73-1.09) 0.25 
Current 209 60 1.06 (0.79-1.42) 0.70 
     
Alcohol intake (g/day)3    0.672 
None 579 202 1.03 (0.87-1.21) 0.75 
<24 g 388 125 0.98 (0.80-1.20) 0.82 
24-48 g 78 25 1.11 (0.70-1.75) 0.67 
>48 g 49 9 0.62 (0.30-1.28) 0.19 
     
Ever use of 
antihistamines4    0.182 
No 983 208 0.99 (0.85-1.15) 0.84 
Yes 48 142 1.30 (0.94-1.82) 0.12 
1Adjusted for age, sex, ethnicity, education, smoking status, family history of pancreatic cancer, 
education, BMI, diabetes, and alcohol intake. Among subgroups, models are not adjusted for the 
subgroup variable 
2P-value for heterogeneity 
3Intake during the year prior to cohort entry 
4Information on antihistamine use missing for 9,053 participants (4.8% of cohort) 
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Table 3-4. Association between antihistamine medication use and pancreatic cancer among 
subgroups of cohort 
 
Subgroup 
Cases with no 
antihistamine use 
Cases with 
antihistamine use RR (95% CI)1 p 
All 1191 190 0.92 (0.78-1.07) 0.26 
     
Age group at baseline    0.362 
<50 80 18 1.11 (0.66-1.87) 0.69 
50-54 103 16 0.82 (0.48-1.40) 0.47 
55-59 167 34 1.04 (0.72-1.51) 0.84 
60-64 206 34 0.91 (0.63-1.32) 0.62 
65-69 334 58 1.03 (0.78-1.37) 0.84 
70+ 301 30 0.66 (0.45-0.96) 0.03 
     
Sex    0.092 
Male 578 76 1.08 (0.85-1.38) 0.52 
Female 613 114 0.82 (0.67-1.00) 0.05 
     
Ethnicity    0.282 
Whites 244 42 0.78 (0.56-1.09) 0.15 
African Americans 221 37 0.76 (0.54-1.08) 0.13 
Latinos 206 33 0.89 (0.62-1.29) 0.54 
Japanese Americans 421 66 1.15 (0.89-1.50) 0.29 
Native Hawaiians 99 12 0.95 (0.52-1.75) 0.88 
     
Follow-up time (years)    0.732 
<5 220 28 0.83 (0.55-1.23) 0.35 
≥5 971 162 0.94 (0.79-1.11) 0.46 
     
Family history of 
pancreatic cancer    0.302 
No 1149 185 0.93 (0.79-1.09) 0.35 
Yes 42 5 0.62 (0.24-1.58) 0.32 
     
Diabetes    0.112 
No 1019 158 0.87 (0.73-1.03) 0.10 
Yes 172 32 1.24 (0.84-1.81) 0.23 
     
Body mass index 
(kg/m2)    0.722 
<25 488 79 0.97 (0.76-1.23) 0.79 
25-30 466 73 0.91 (0.71-1.17) 0.46 
≥30 237 38 0.83 (0.59-1.18) 0.30 
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Smoking status    0.812 
Never 503 89 0.97 (0.77-1.22) 0.79 
Past 464 71 0.86 (0.67-1.11) 0.24 
Current 224 30 0.90 (0.61-1.22) 0.60 
     
Alcohol intake (g/day)3    0.792 
None 634 97 0.88 (0.71-1.09) 0.23 
<24 g 421 76 1.00 (0.78-1.27) 0.97 
24-48 g 87 10 0.77 (0.40-1.49) 0.44 
>48 g 49 7 0.93 (0.42-2.07) 0.86 
1Adjusted for age, sex, ethnicity, education, smoking status, family history of pancreatic cancer, 
education, BMI, diabetes, and alcohol intake. Among subgroups, models are not adjusted for the 
subgroup variable 
2P-value for heterogeneity 
3Intake during the year prior to cohort entry
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Table 4-1. Baseline characteristics of Kaiser Permanente Southern California patients from 2006-2016, by diabetes status 
 
 
Total  
(N=1,499,627) 
No diabetes  
(N=1,055,996) 
Incident diabetes  
(N=110,699) 
Prevalent diabetes 
(N=332,932) 
Characteristic N % N % N % N % 
Pancreatic cancer cases 2,002 0.1 937 0.1 306 0.3 759 0.2 
Person-years, total 7,462,072.5  5,060,344.5  726,055.0  1,675,673.1  
Follow-up time (years), mean (SD) 5.0 (3.0)  4.8 (2.9)  6.6 (2.5)  5.0 (3.0)  
Time to pancreatic cancer (years), 
mean (SD) 3.8 (2.5) 
 
3.6 (2.5) 
 
4.3 (2.4) 
 
3.7 (2.5) 
 
Incidence rate, age-adjusted1 30.7 
 
23.8 
 
43.7 
 
41.2 
 
Age, mean (SD) 57.9 (10.9)  56.5 (10.5)  59.5 (10.8)  61.8 (11.2)  
Age group  
 
 
 
 
 
 
 
45-50 433,225 28.9 353,854 33.5 23,417 21.2 55,954 16.8 
50-54 249,754 16.7 187,661 17.8 19,124 17.3 42,969 12.9 
55-59 227,267 15.2 158,721 15.0 18,244 16.5 50,302 15.1 
60-64 191,088 12.7 125,114 11.9 15,673 14.2 50,301 15.1 
65-69 153,534 10.2 93,519 8.9 12,945 11.7 47,070 14.1 
≥70 244,759 16.3 137,127 13.0 21,296 19.2 86,336 25.9 
Gender         
Female 827,460 55.2 608,694 57.6 59,145 53.4 159,621 47.9 
Male 672,167 44.8 447,302 42.4 51,554 46.6 173,311 52.1 
Race/ethnicity         
Asian 166,395 11.1 110,579 10.5 14,836 13.4 40,980 12.3 
Black 160,228 10.7 103,112 9.8 14,730 13.3 42,386 12.7 
Hispanic 487,185 32.5 327,726 31.0 36,892 33.3 122,567 36.8 
White 685,819 45.7 514,579 48.7 44,241 40.0 126,999 38.2 
BMI kg/m2, mean (SD) 29.2 (6.2)  28.3 (5.7)  31.2 (6.5)  31.2 (6.8)  
BMI kg/m2 category  
 
 
 
 
 
 
 
<25 379,339 25.3 308,552 29.2 16,887 15.3 53,900 16.2 
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25-30 555,925 37.1 410,837 38.9 36,280 32.8 108,808 32.7 
≥30 564,363 37.6 336,607 31.9 57,532 52.0 170,224 51.1 
Smoking status  
 
 
 
 
 
 
 
Never 967,251 64.5 703,859 66.7 67,582 61.1 195,810 58.8 
Past 392,214 26.2 253,045 24.0 30,909 27.9 108,260 32.5 
Current 140,162 9.4 99,092 9.4 12,208 11.0 28,862 8.7 
Alcohol user  
 
 
 
 
 
 
 
No 864,634 57.7 570,286 54.0 67,683 61.1 226,665 68.1 
Yes 634,993 42.3 485,710 46.0 43,016 38.9 106,267 31.9 
Education2  
 
 
 
 
 
 
 
High school or less 586,579 39.1 388,368 36.8 47,785 43.2 150,426 45.2 
Some college 523,205 34.9 370,140 35.1 40,980 37.0 112,085 33.7 
College graduate 318,594 21.2 243,112 23.0 19,828 17.9 55,654 16.7 
Missing 71,249 4.8 54,376 5.2 2,106 1.9 14,767 4.4 
Family history of pancreatic cancer 16,066 1.1 12,068 1.1 1,063 1.0 2,935 0.9 
Pancreatitis 18,418 1.2 8,510 0.8 1,403 1.3 8,505 2.6 
1Incidence rate per 100,000 person-years, age-standardized to US Census 2000 standard population, truncated to ages 45+ 
2Based on population geocoding files and not specific to individual patient 
All tests comparing distribution of risk factors across diabetes status had p-values <0.0001 
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Table 4-2. Association between diabetes status and pancreatic cancer, among the entire cohort and within race/ethnicity 
subgroups 
 
 
Total  
(N=1,499,627) 
Asian 
(N=166,395) 
Black 
(N=160,228) 
Hispanic 
(N=487,185) 
White  
(N=685,819)  
Exposure 
N Cases/ 
Person-
years 
RR  
(95% CI)1 
N Cases/ 
Person-
years 
RR  
(95% CI)1 
N Cases/ 
Person-
years 
RR  
(95% CI)1 
N Cases/ 
Person-
years 
RR  
(95% CI)1 
N Cases/ 
Person-
years 
RR  
(95% CI)1 p2 
Diabetes status           0.25 
None 
937/ 
5,060,344.5 1 (ref) 
67/ 
519,170.1 1 (ref) 
117/ 
528,713.0 1 (ref) 
116/ 
1,439,741.3 1 (ref) 
587/ 
2,572,720.0 1 (ref)  
Incident 
306/ 
726,055.0 
3.17  
(2.75-3.65) 
34/  
98,859.0 
3.21  
(2.04-5.03) 
37/ 
100,617.6 
2.82  
(1.91-4.14) 
82/ 
235,261.2 
4.12  
(3.10-5.47) 
153/ 
291,317.3 
2.90  
(2.37-3.53)  
Prevalent 
759/ 
1,675,673.1 
1.85  
(1.67-2.05) 
73/ 
211,612.1 
1.72  
(1.22-2.43) 
116/ 
230,597.3 
1.74  
(1.33-2.28) 
213/ 
579,355.2 
2.19  
(1.77-2.71) 
357/ 
654,108.5 
1.77  
(1.54-2.03)  
Diabetes duration          0.09 
None 
937/ 
5,060,344.5 1 (ref) 
67/ 
519,170.1 1 (ref) 
117/ 
528,713.0 1 (ref) 
166/ 
1,439,741.3 1 (ref) 
587/ 
2,572,720.0 1 (ref)  
Incident ≤1 yr 
175/ 
102,711.5 
6.91  
(5.76-8.30) 
19/ 
13,729.9 
7.48  
(4.17-13.41) 
20/ 
13,540.9 
6.01  
(3.68-9.82) 
38/ 
34,371.0 
7.50  
(5.09-11.06) 
98/ 
41,069.8 
6.89  
(5.37-8.83)  
Incident >1 yr 
131/ 
623,343.4 
1.96  
(1.62-2.38) 
15/ 
85,129.1 
2.25  
(1.24-4.10) 
17/ 
87,076.7 
1.65  
(0.97-2.80) 
44/ 
200,890.2 
2.73  
(1.91-3.89) 
55/ 
250,247.5 
1.65  
(1.24-2.19)  
NOTE: Incident diabetes status and duration treated as time-varying exposures 
1From a Cox proportional hazards regression with age at cohort entry, gender, race, smoking, BMI, alcohol, pancreatitis, family history of pancreatic cancer and 
education as covariates 
2P-values for heterogeneity across race/ethnicity  
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Table 4-3. Association between diabetes status and pancreatic cancer, among specific subgroups 
 
 No diabetes Incident diabetes Prevalent diabetes  
Subgroup 
N 
Cases 
Person-
years RR (95% CI)1 
N 
Cases 
Person-
years RR (95% CI)1 
N 
Cases 
Person-
years RR (95% CI)1 p2 
Gender          0.75 
Females 521 2,993,149.9 1 (ref) 171 396,488.0 3.27 (2.70-3.96) 355 2,067,194.6 1.85 (1.61-2.14)  
Males 416 2,067,194.6 1 (ref) 135 329,567.0 3.05 (2.48-3.76) 404 849,473.1 1.85 (1.60-2.14)  
BMI (kg/m2)          0.40 
<25 303 1,516,627.4 1 (ref) 55 108,002.9 2.89 (2.10-3.99) 142 262,633.0 1.76 (1.42-2.17)  
25-30 373 1,985,713.6 1 (ref) 125 241,533.6 3.62 (2.91-4.51) 284 554,451.0 1.96 (1.66-2.30)  
≥30 261 1,558,003.5 1 (ref) 126 376,518.5 2.88 (2.29-3.61) 333 858,589.1 1.79 (1.51-2.11)  
Smoking status          0.02 
Never 501 3,377,796.1 1 (ref) 172 447,694.9 3.35 (2.77-4.06) 428 992,526.0 2.13 (1.86-2.44)  
Past 313 1,232,906.0 1 (ref) 97 200,397.7 3.02 (2.36-3.85) 251 546,545.1 1.50 (1.26-1.79)  
Current 123 449,642.3 1 (ref) 37 77,962.4 2.81 (1.87-4.22) 80 136,602.0 1.75 (1.29-2.36)  
Alcohol user          0.86 
No 509 2,745,676.0 1 (ref) 185 444,507.4 3.11 (2.59-3.73) 534 1,146,417.6 1.85 (1.63-2.11)  
Yes 428 2,314,668.5 1 (ref) 121 281,547.6 3.30 (2.63-4.13) 225 529,255.4 1.85 (1.56-2.19)  
Pancreatitis          0.10 
No 912 5,017,861.9 1 (ref) 295 717,016.4 3.20 (2.77-3.69) 728 1,633,082.8 1.89 (1.70-2.09)  
Yes 25 42,482.6 1 (ref) 11 9,038.6 2.06 (0.83-5.09) 31 42,590.3 1.03 (0.61-1.74)   
Note: Incident diabetes treated as a time-varying exposure 
1From a Cox proportional hazards regression with age at cohort entry, gender, race, smoking, BMI, alcohol, pancreatitis, family history of pancreatic cancer and 
education as covariates 
2P-values for heterogeneity across particular subgroup 
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Table 4-4. Association between incident diabetes duration and pancreatic cancer, among specific subgroups 
 
 No diabetes Incident diabetes ≤1 year Incident diabetes >1 year  
Subgroup 
N 
Cases 
Person-
years RR (95% CI)1 
N 
Cases 
Person-
years RR (95% CI)1 
N 
Cases 
Person-
years RR (95% CI)1 p2 
Gender          0.09 
Female 521 2,993,149.9 1 (ref) 91 54,946.7 6.42 (4.94-8.33) 80 341,541.2 2.29 (1.79-2.93)  
Male 416 2,067,194.6 1 (ref) 84 47,764.8 7.42 (5.74-9.58) 51 281,802.2 1.60 (1.18-2.17)  
BMI (kg/m2)          0.35 
<25 303 1,516,627.4 1 (ref) 36 18,627.6 6.51 (4.34-9.76) 19 89,375.3 1.61 (1.00-2.59)  
25-30 373 1,985,713.6 1 (ref) 73 35,958.6 8.32 (6.29-11.00) 52 205,575.0 2.15 (1.60-2.91)  
≥30 261 1,558,003.5 1 (ref) 66 48,125.3 5.91 (4.39-7.97) 60 328,393.2 1.97 (1.46-2.65)  
Smoking status          0.63 
Never 501 3,377,796.1 1 (ref) 101 62,999.4 7.67 (5.99-9.81) 71 384,695.5 2.02 (1.55-2.62)  
Past 313 1,232,906.0 1 (ref) 52 27,922.0 6.07 (4.39-8.38) 45 172,475.7 2.03 (1.47-2.81)  
Current 123 449,642.3 1 (ref) 22 11,790.2 6.33 (3.83-10.46) 15 66,172.2 1.57 (0.88-2.81)  
Alcohol user          0.52 
No 509 2,745,676.0 1 (ref) 101 61,959.7 6.46 (5.08-8.21) 84 382,547.7 2.03 (1.59-2.59)  
Yes 428 2,314,668.5 1 (ref) 74 40,751.8 7.67 (5.79-10.16) 47 240,795.8 1.85 (1.35-2.54)   
Note: Incident diabetes duration treated as time-varying exposure 
1From a Cox proportional hazards regression with age at cohort entry, gender, race, smoking, BMI, alcohol, pancreatitis, family history of pancreatic cancer and 
education as covariates 
2P-values for heterogeneity across particular subgroup 
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Table 4-5. Association between percent difference and rate of change in glucose, HbA1c and weight and pancreatic cancer, 
among incident diabetics in the entire cohort and within race/ethnicity subgroups 
 
 Total Asian Black Hispanic White  
Parameter RR (95% CI)1 RR (95% CI)1 RR (95% CI)1 RR (95% CI)1 RR (95% CI)1 p2 
Glucose       
Percent difference (per 10% unit increase) 1.04 (1.03-1.05) 1.12 (1.06-1.17) 1.06 (1.02-1.09) 1.05 (0.99-1.10) 1.04 (1.02-1.05) 0.02 
Rate of change (per mg/dL/month increase) 1.06 (1.04-1.07) 1.13 (1.07-1.19) 1.07 (1.03-1.11) 1.05 (0.97-1.13) 1.05 (1.03-1.07) 0.06 
HbA1c       
Percent difference (per 1% unit increase) 1.02 (1.02-1.03) 1.02 (0.92-1.14) 1.02 (0.99-1.04) 1.01 (0.97-1.04) 1.03 (1.02-1.04) 0.41 
Rate of change (per 0.1%/month increase) 1.45 (1.26-1.66) 2.06 (0.34-12.66) 1.32 (0.89-1.96) 1.23 (0.76-2.00) 1.60 (1.37-1.88) 0.39 
Weight       
Percent difference (per 3% unit decrease) 1.24 (1.18-1.31) 1.22 (1.03-1.45) 1.07 (0.92-1.26) 1.14 (1.01-1.29) 1.32 (1.24-1.40) 0.02 
Rate of change (per kg/month decrease) 1.62 (1.44-1.82) 1.78 (1.02-3.11) 1.17 (0.75-1.83) 1.54 (1.15-2.08) 1.74 (1.51-2.00) 0.34 
1From a Cox proportional hazards regression with age at diabetes diagnosis, gender, race, smoking, and BMI as covariates. BMI was not included as a covariate 
for the models assessing changes in weight 
2P-values for heterogeneity across race/ethnicity 
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Table 5-1. Baseline characteristics of 162 patients with primary tumor samples in TCGA, 
by vital status 
 
 Total (N=162) Alive (N=105) Dead (N=57)  
Characteristic N % N % N % p1 
Follow-up time (mos), 
median (IQR) 7.7 (3.1, 16.8) 6.0 (0.9, 12.6) 14.3 (5.1, 20.6) 0.002 
Age, mean (SD) 65.5 (10.7) 64.7 (10.8) 67.1 (10.6) 0.176 
Gender       0.170 
  Female 70 43.2 50 47.6 20 35.1  
  Male 92 56.8 55 52.4 37 64.9  
Stage       0.108 
  I 20 12.3 17 16.2 3 5.3  
  II 130 80.2 79 75.2 51 89.5  
  III/IV 9 5.6 6 5.7 3 5.3  
  Missing 3 1.9 3 2.9 0 0.0  
Smoking status       0.811 
Never 57 35.2 32 30.5 25 43.9  
Former 58 35.8 36 34.3 22 38.6  
Current 17 10.5 10 9.5 7 12.3  
Missing 30 18.5 27 25.7 3 5.3  
Received radiation       0.030 
No 93 57.4 46 43.8 47 82.5  
Yes 28 17.3 21 20.0 7 12.3  
Missing 41 25.3 38 36.2 3 5.3  
1Mann-Whitney U test for follow-up time, t-test for age, chi-square test for all other variables
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Table 5-2. Hazard ratios and 95% confidence intervals for the top associations between methylation in CpG loci and 
pancreatic cancer survival 
 
       Expression Minimally adjusted1 Fully adjusted2 
CpG site Chr Position 
UCSC 
Gene 
Name 
UCSC Gene 
Group Chromatin state 
Beta value, 
median (IQR) 
Spearman's 
correlation 
coefficient p HR (95% CI) p HR (95% CI) p 
IL10             
cg14789529 chr1 206941464 IL10 3'UTR Weak transcription 0.75 (0.68, 0.81) -0.253 0.001 0.96 (0.93, 0.98) 0.001 0.97 (0.94, 1.00) 0.027 
cg10978799 chr1 206945924 IL10 TSS200 Quiescent/Low 0.67 (0.56, 0.76) -0.446 0.000 0.98 (0.97, 1.00) 0.063 0.99 (0.97, 1.01) 0.271 
             
TGFB2             
cg16658719 chr1 218518963 TGFB2 TSS1500 Active TSS 0.04 (0.03, 0.04) 0.035 0.662 1.34 (1.08, 1.66) 0.007 1.58 (1.21, 2.06) 0.001 
cg16361301 chr1 218519549 TGFB2 1stExon;5'UTR Active TSS 0.05 (0.03, 0.06) 0.043 0.596 1.18 (1.01, 1.39) 0.039 1.19 (1.00, 1.41) 0.046 
cg06899755 chr1 218520325 TGFB2 1stExon Active TSS 0.08 (0.06, 0.10) -0.291 0.000 0.96 (0.92, 1.01) 0.092 0.98 (0.92, 1.03) 0.385 
cg01558923 chr1 218520959 TGFB2 Body 
Flanking Active 
TSS 0.07 (0.05, 0.11) -0.241 0.002 0.98 (0.95, 1.00) 0.080 1.00 (0.97, 1.03) 0.860 
cg20698667 chr1 218523325 TGFB2 Body Weak transcription 0.64 (0.55, 0.75) -0.174 0.030 1.00 (0.99, 1.02) 0.871 1.02 (1.00, 1.05) 0.049 
cg07810039 chr1 218524558 TGFB2 Body Weak transcription 0.44 (0.31, 0.60) -0.441 0.000 0.98 (0.97, 0.99) 0.002 0.99 (0.97, 1.00) 0.091 
cg25132662 chr1 218537543 TGFB2 Body Enhancers 0.34 (0.26, 0.43) 0.143 0.074 1.02 (1.00, 1.04) 0.097 1.01 (0.99, 1.04) 0.298 
cg10484211 chr1 218547935 TGFB2 Body Weak transcription 0.36 (0.26, 0.46) -0.193 0.016 0.98 (0.97, 1.00) 0.075 0.98 (0.96, 1.00) 0.115 
cg16967578 chr1 218575437 TGFB2 Body Weak transcription 0.82 (0.75, 0.88) 0.141 0.078 1.05 (1.01, 1.08) 0.005 1.05 (1.01, 1.10) 0.020 
             
TNF             
cg14910524 chr6 31541948 TNF 3'UTR;TSS1500 Quiescent/Low 0.81 (0.78, 0.83) -0.270 0.001 1.05 (1.00, 1.09) 0.034 1.02 (0.97, 1.08) 0.403 
cg27531490 chr6 31542459 TNF TSS1500 Quiescent/Low 0.54 (0.48, 0.60) 0.193 0.015 1.02 (1.00, 1.05) 0.078 1.01 (0.98, 1.04) 0.349 
cg24452282 chr6 31542740 TNF TSS1500 Quiescent/Low 0.62 (0.54, 0.69) -0.256 0.001 1.03 (1.01, 1.05) 0.008 1.01 (0.98, 1.04) 0.485 
cg21370522 chr6 31543219 TNF TSS200 Quiescent/Low 0.36 (0.28, 0.45) -0.352 0.000 0.98 (0.96, 1.00) 0.020 1.00 (0.97, 1.02) 0.730 
cg20477259 chr6 31544960 TNF Body Quiescent/Low 0.55 (0.47, 0.63) -0.207 0.009 1.04 (1.01, 1.07) 0.010 1.03 (0.99, 1.06) 0.168 
cg09637172 chr6 31545252 TNF Body Weak transcription 0.87 (0.78, 0.92) -0.397 0.000 1.05 (1.01, 1.08) 0.004 1.03 (1.00, 1.07) 0.091 
cg05952498 chr6 31545257 TNF Body Weak transcription 0.75 (0.67, 0.82) -0.337 0.000 1.04 (1.01, 1.07) 0.003 1.03 (0.99, 1.06) 0.144 
cg26736341 chr6 31545342 TNF 3'UTR Weak transcription 0.58 (0.52, 0.64) -0.152 0.057 1.02 (1.00, 1.05) 0.085 1.01 (0.97, 1.04) 0.709 
cg04472685 chr6 31545473 TNF 3'UTR Weak transcription 0.77 (0.69, 0.81) -0.358 0.000 1.05 (1.01, 1.09) 0.005 1.04 (0.99, 1.10) 0.105 
cg19124225 chr6 31545836 TNF 3'UTR Weak transcription 0.85 (0.77, 0.89) 0.016 0.842 1.05 (1.01, 1.08) 0.010 1.03 (0.99, 1.08) 0.127 
             
IL6             
cg10140158 chr7 22765750 IL6 TSS1500 Enhancers 0.82 (0.73, 0.86) 0.107 0.183 1.02 (1.00, 1.04) 0.095 1.01 (0.99, 1.04) 0.345 
cg26061582 chr7 22766209 IL6 TSS1500 Enhancers 0.05 (0.04, 0.07) 0.050 0.537 0.91 (0.83, 1.00) 0.057 0.94 (0.85, 1.05) 0.281 
cg00087425 chr7 22766829 IL6 1stExon;5'UTR 
Flanking Active 
TSS 0.16 (0.10, 0.30) -0.127 0.112 1.00 (0.99, 1.02) 0.834 1.02 (1.00, 1.04) 0.084 
cg15703690 chr7 22766992 IL6 Body Flanking Active 0.16 (0.12, 0.21) -0.072 0.371 1.01 (0.99, 1.03) 0.189 1.03 (1.00, 1.05) 0.024 
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TSS 
cg07998387 chr7 22767571 IL6 Body Quiescent/Low 0.63 (0.56, 0.68) 0.052 0.521 1.02 (1.00, 1.04) 0.028 1.01 (0.99, 1.04) 0.423 
             
TGFB3             
cg13121428 chr14 76446161 TGFB3 Body Active TSS 0.79 (0.73, 0.84) -0.415 0.000 0.97 (0.94, 1.00) 0.030 0.98 (0.95, 1.02) 0.316 
cg24696715 chr14 76446681 TGFB3 Body 
Flanking Active 
TSS 0.56 (0.51, 0.63) -0.466 0.000 0.96 (0.93, 0.99) 0.016 0.98 (0.95, 1.02) 0.275 
cg18298494 chr14 76447327 TGFB3 1stExon;5'UTR 
Flanking Active 
TSS 0.57 (0.49, 0.63) -0.282 0.000 0.98 (0.95, 1.00) 0.043 0.99 (0.97, 1.02) 0.565 
cg08615333 chr14 76447413 TGFB3 1stExon;5'UTR 
Flanking Active 
TSS 0.63 (0.53, 0.71) -0.167 0.036 0.98 (0.97, 1.00) 0.054 0.99 (0.97, 1.01) 0.516 
cg03395898 chr14 76448011 TGFB3 1stExon;5'UTR Active TSS 0.17 (0.12, 0.22) 0.256 0.001 0.97 (0.94, 1.00) 0.093 0.99 (0.95, 1.03) 0.580 
cg16292972 chr14 76448509 TGFB3 TSS1500 Active TSS 0.04 (0.03, 0.04) 0.066 0.414 1.18 (0.88, 1.59) 0.265 1.45 (1.01, 2.09) 0.044 
             
TGFB1             
cg04614483 chr19 41836950 TGFB1 3'UTR Weak transcription 0.49 (0.41, 0.55) 0.519 0.000 1.03 (1.01, 1.05) 0.016 1.01 (0.98, 1.04) 0.478 
cg11037750 chr19 41837015 TGFB1 Body Weak transcription 0.72 (0.63, 0.77) 0.506 0.000 1.04 (1.01, 1.06) 0.002 1.02 (1.00, 1.05) 0.087 
cg09926389 chr19 41837123 TGFB1 Body Weak transcription 0.76 (0.62, 0.88) 0.438 0.000 1.03 (1.01, 1.04) 0.000 1.02 (1.00, 1.03) 0.053 
cg15735736 chr19 41854950 TGFB1 Body Weak transcription 0.41 (0.33, 0.49) -0.092 0.251 0.98 (0.96, 1.00) 0.019 0.99 (0.97, 1.01) 0.376 
cg15726807 chr19 41857198 TGFB1 Body 
Flanking Active 
TSS 0.09 (0.07, 0.12) -0.255 0.001 0.96 (0.92, 1.00) 0.079 1.01 (0.95, 1.08) 0.649 
cg21198010 chr19 41857456 TGFB1 Body 
Flanking Active 
TSS 0.03 (0.03, 0.04) -0.057 0.481 1.09 (0.78, 1.52) 0.630 1.37 (0.95, 1.96) 0.091 
cg03313751 chr19 41857626 TGFB1 Body 
Flanking Active 
TSS 0.03 (0.03, 0.04) -0.295 0.000 1.64 (1.17, 2.30) 0.004 1.62 (1.14, 2.31) 0.007 
cg00389176 chr19 41859014 TGFB1 1stExon;5'UTR 
Flanking Active 
TSS 0.06 (0.05, 0.06) 0.012 0.878 1.23 (0.98, 1.53) 0.074 1.07 (0.79, 1.45) 0.670 
cg24767336 chr19 41860095 TGFB1 TSS1500 
Flanking Active 
TSS 0.03 (0.02, 0.03) -0.223 0.005 1.15 (0.92, 1.44) 0.211 1.46 (1.06, 2.02) 0.020 
1Adjusted for age and sex 
2Adjusted for age, sex, stage and five surrogate variables 
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Table 5-3. Hazard ratios and 95% confidence intervals for the associations between methylation in CpG loci and pancreatic 
cancer survival 
 
       Expression Minimally adjusted1 Fully adjusted2 
CpG site Chr Position 
UCSC 
Gene 
Name 
UCSC Gene 
Group Chromatin state 
Beta value, 
median (IQR) 
Spearman's 
correlation 
coefficient p HR (95% CI) p HR (95% CI) p 
IL10             
cg14789529 chr1 206941464 IL10 3'UTR Weak transcription 0.75 (0.68, 0.81) -0.253 0.001 0.96 (0.93, 0.98) 0.001 0.97 (0.94, 1.00) 0.027 
cg15096505 chr1 206943566 IL10 Body Quiescent/Low 0.84 (0.80, 0.88) -0.310 0.000 1.01 (0.98, 1.04) 0.627 0.99 (0.95, 1.02) 0.450 
cg17067005 chr1 206945346 IL10 Body Quiescent/Low 0.93 (0.92, 0.94) 0.101 0.207 1.11 (0.94, 1.31) 0.230 1.00 (0.90, 1.12) 0.953 
cg10978799 chr1 206945924 IL10 TSS200 Quiescent/Low 0.67 (0.56, 0.76) -0.446 0.000 0.98 (0.97, 1.00) 0.063 0.99 (0.97, 1.01) 0.271 
cg17744604 chr1 206946166 IL10 TSS1500 Quiescent/Low 0.82 (0.75, 0.87) -0.573 0.000 0.98 (0.95, 1.01) 0.159 0.99 (0.96, 1.03) 0.580 
cg14180511 chr1 206946187 IL10 TSS1500 Quiescent/Low 0.78 (0.71, 0.83) -0.516 0.000 0.98 (0.96, 1.01) 0.286 1.00 (0.97, 1.04) 0.885 
             
TGFB2             
cg21387604 chr1 218518468 TGFB2 TSS1500 Flanking Active TSS 0.11 (0.07, 0.16) -0.083 0.304 0.99 (0.95, 1.04) 0.722 0.98 (0.93, 1.03) 0.437 
cg16899280 chr1 218518579 TGFB2 TSS1500 Flanking Active TSS 0.04 (0.03, 0.04) -0.125 0.118 1.02 (0.82, 1.28) 0.841 1.00 (0.76, 1.33) 0.980 
cg26343258 chr1 218518675 TGFB2 TSS1500 Flanking Active TSS 0.07 (0.06, 0.08) -0.053 0.513 1.07 (0.95, 1.20) 0.250 1.04 (0.91, 1.18) 0.591 
cg16658719 chr1 218518963 TGFB2 TSS1500 Active TSS 0.04 (0.03, 0.04) 0.035 0.662 1.34 (1.08, 1.66) 0.007 1.58 (1.21, 2.06) 0.001 
cg25851842 chr1 218519232 TGFB2 TSS200 Active TSS 0.02 (0.02, 0.02) 0.064 0.425 1.01 (0.97, 1.05) 0.666 1.00 (0.97, 1.04) 0.943 
cg16361301 chr1 218519549 TGFB2 1stExon;5'UTR Active TSS 0.05 (0.03, 0.06) 0.043 0.596 1.18 (1.01, 1.39) 0.039 1.19 (1.00, 1.41) 0.046 
cg08746138 chr1 218519552 TGFB2 1stExon;5'UTR Active TSS 0.05 (0.04, 0.05) -0.044 0.584 0.92 (0.66, 1.28) 0.635 0.98 (0.69, 1.40) 0.917 
cg12461345 chr1 218519565 TGFB2 1stExon;5'UTR Active TSS 0.03 (0.02, 0.03) 0.077 0.336 1.47 (0.82, 2.63) 0.192 1.20 (0.62, 2.33) 0.582 
cg09167119 chr1 218519576 TGFB2 1stExon;5'UTR Active TSS 0.03 (0.03, 0.03) -0.051 0.526 0.76 (0.48, 1.22) 0.261 0.93 (0.49, 1.77) 0.827 
cg11976166 chr1 218520090 TGFB2 1stExon Active TSS 0.09 (0.08, 0.12) -0.244 0.002 1.00 (0.96, 1.04) 0.973 1.03 (0.98, 1.08) 0.287 
cg06899755 chr1 218520325 TGFB2 1stExon Active TSS 0.08 (0.06, 0.10) -0.291 0.000 0.96 (0.92, 1.01) 0.092 0.98 (0.92, 1.03) 0.385 
cg13285637 chr1 218520435 TGFB2 Body Flanking Active TSS 0.07 (0.06, 0.08) -0.037 0.644 0.96 (0.88, 1.05) 0.389 0.95 (0.85, 1.07) 0.415 
cg22021178 chr1 218520468 TGFB2 Body Flanking Active TSS 0.02 (0.02, 0.02) -0.254 0.001 0.81 (0.63, 1.04) 0.104 0.89 (0.73, 1.10) 0.282 
cg27508144 chr1 218520789 TGFB2 Body Flanking Active TSS 0.07 (0.05, 0.11) -0.355 0.000 0.99 (0.97, 1.01) 0.341 1.00 (0.97, 1.04) 0.845 
cg17934824 chr1 218520792 TGFB2 Body Flanking Active TSS 0.02 (0.02, 0.03) -0.315 0.000 0.99 (0.97, 1.01) 0.488 1.01 (0.98, 1.04) 0.405 
cg01558923 chr1 218520959 TGFB2 Body Flanking Active TSS 0.07 (0.05, 0.11) -0.241 0.002 0.98 (0.95, 1.00) 0.080 1.00 (0.97, 1.03) 0.860 
cg20698667 chr1 218523325 TGFB2 Body Weak transcription 0.64 (0.55, 0.75) -0.174 0.030 1.00 (0.99, 1.02) 0.871 1.02 (1.00, 1.05) 0.049 
cg07810039 chr1 218524558 TGFB2 Body Weak transcription 0.44 (0.31, 0.60) -0.441 0.000 0.98 (0.97, 0.99) 0.002 0.99 (0.97, 1.00) 0.091 
cg25132662 chr1 218537543 TGFB2 Body Enhancers 0.34 (0.26, 0.43) 0.143 0.074 1.02 (1.00, 1.04) 0.097 1.01 (0.99, 1.04) 0.298 
cg10484211 chr1 218547935 TGFB2 Body Weak transcription 0.36 (0.26, 0.46) -0.193 0.016 0.98 (0.97, 1.00) 0.075 0.98 (0.96, 1.00) 0.115 
cg18876728 chr1 218557095 TGFB2 Body Weak transcription 0.80 (0.65, 0.86) -0.173 0.030 1.00 (0.99, 1.02) 0.793 1.00 (0.98, 1.02) 0.733 
cg16967578 chr1 218575437 TGFB2 Body Weak transcription 0.82 (0.75, 0.88) 0.141 0.078 1.05 (1.01, 1.08) 0.005 1.05 (1.01, 1.10) 0.020 
cg20991819 chr1 218617769 TGFB2 3'UTR Quiescent/Low 0.72 (0.65, 0.80) 0.311 0.000 1.01 (0.99, 1.03) 0.187 1.01 (0.99, 1.04) 0.386 
             
IL8             
cg16468729 chr4 74606465 IL8 Body Quiescent/Low 0.13 (0.10, 0.16) 0.155 0.053 1.03 (0.97, 1.09) 0.363 1.01 (0.93, 1.10) 0.828 
cg04392234 chr4 74608458 IL8 3'UTR Quiescent/Low 0.84 (0.77, 0.89) -0.054 0.502 0.98 (0.95, 1.02) 0.281 0.97 (0.92, 1.03) 0.310 
             
TNF             
cg14910524 chr6 31541948 TNF 3'UTR;TSS1500 Quiescent/Low 0.81 (0.78, 0.83) -0.270 0.001 1.05 (1.00, 1.09) 0.034 1.02 (0.97, 1.08) 0.403 
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cg27531490 chr6 31542459 TNF TSS1500 Quiescent/Low 0.54 (0.48, 0.60) 0.193 0.015 1.02 (1.00, 1.05) 0.078 1.01 (0.98, 1.04) 0.349 
cg24452282 chr6 31542740 TNF TSS1500 Quiescent/Low 0.62 (0.54, 0.69) -0.256 0.001 1.03 (1.01, 1.05) 0.008 1.01 (0.98, 1.04) 0.485 
cg11484872 chr6 31543169 TNF TSS200 Quiescent/Low 0.69 (0.60, 0.75) -0.340 0.000 1.00 (0.98, 1.03) 0.795 1.00 (0.97, 1.02) 0.739 
cg21370522 chr6 31543219 TNF TSS200 Quiescent/Low 0.36 (0.28, 0.45) -0.352 0.000 0.98 (0.96, 1.00) 0.020 1.00 (0.97, 1.02) 0.730 
cg01569083 chr6 31543289 TNF TSS200 Quiescent/Low 0.38 (0.30, 0.46) -0.178 0.025 0.99 (0.97, 1.02) 0.622 0.99 (0.97, 1.02) 0.656 
cg03037030 chr6 31543300 TNF TSS200 Quiescent/Low 0.26 (0.20, 0.35) -0.166 0.038 1.00 (0.97, 1.02) 0.854 1.00 (0.97, 1.02) 0.958 
cg12681001 chr6 31543540 TNF 1stExon Quiescent/Low 0.29 (0.23, 0.36) -0.178 0.026 0.99 (0.97, 1.02) 0.532 1.00 (0.97, 1.03) 0.959 
cg21222743 chr6 31543545 TNF 1stExon Quiescent/Low 0.29 (0.23, 0.35) -0.258 0.001 0.99 (0.97, 1.02) 0.690 1.00 (0.97, 1.03) 0.957 
cg10717214 chr6 31543557 TNF 1stExon Quiescent/Low 0.32 (0.27, 0.37) -0.193 0.015 1.01 (0.98, 1.04) 0.723 1.00 (0.96, 1.04) 0.983 
cg04425624 chr6 31543565 TNF 1stExon Quiescent/Low 0.44 (0.39, 0.51) -0.229 0.004 1.01 (0.98, 1.03) 0.537 1.00 (0.97, 1.03) 0.856 
cg21467614 chr6 31543638 TNF 1stExon Quiescent/Low 0.50 (0.43, 0.58) -0.316 0.000 1.01 (0.99, 1.03) 0.391 1.00 (0.98, 1.02) 0.928 
cg08553327 chr6 31543647 TNF 1stExon Quiescent/Low 0.59 (0.50, 0.65) -0.314 0.000 0.99 (0.97, 1.02) 0.489 0.99 (0.96, 1.02) 0.371 
cg26729380 chr6 31543655 TNF 1stExon Quiescent/Low 0.50 (0.43, 0.57) -0.345 0.000 1.00 (0.97, 1.03) 0.938 1.00 (0.97, 1.03) 0.947 
cg10650821 chr6 31543686 TNF 1stExon Quiescent/Low 0.42 (0.36, 0.49) -0.294 0.000 1.02 (1.00, 1.05) 0.112 1.00 (0.97, 1.03) 0.942 
cg17741993 chr6 31544694 TNF Body Quiescent/Low 0.80 (0.70, 0.87) -0.409 0.000 1.00 (0.98, 1.03) 0.723 1.01 (0.99, 1.04) 0.325 
cg01360627 chr6 31544931 TNF Body Quiescent/Low 0.81 (0.71, 0.88) -0.393 0.000 1.02 (0.99, 1.04) 0.203 1.02 (0.99, 1.05) 0.261 
cg23384708 chr6 31544934 TNF Body Quiescent/Low 0.67 (0.60, 0.73) -0.405 0.000 1.00 (0.97, 1.04) 0.763 1.00 (0.97, 1.04) 0.839 
cg20477259 chr6 31544960 TNF Body Quiescent/Low 0.55 (0.47, 0.63) -0.207 0.009 1.04 (1.01, 1.07) 0.010 1.03 (0.99, 1.06) 0.168 
cg09637172 chr6 31545252 TNF Body Weak transcription 0.87 (0.78, 0.92) -0.397 0.000 1.05 (1.01, 1.08) 0.004 1.03 (1.00, 1.07) 0.091 
cg05952498 chr6 31545257 TNF Body Weak transcription 0.75 (0.67, 0.82) -0.337 0.000 1.04 (1.01, 1.07) 0.003 1.03 (0.99, 1.06) 0.144 
cg15989608 chr6 31545321 TNF 3'UTR Weak transcription 0.71 (0.65, 0.77) -0.371 0.000 1.02 (0.99, 1.05) 0.145 1.01 (0.97, 1.05) 0.575 
cg26736341 chr6 31545342 TNF 3'UTR Weak transcription 0.58 (0.52, 0.64) -0.152 0.057 1.02 (1.00, 1.05) 0.085 1.01 (0.97, 1.04) 0.709 
cg04472685 chr6 31545473 TNF 3'UTR Weak transcription 0.77 (0.69, 0.81) -0.358 0.000 1.05 (1.01, 1.09) 0.005 1.04 (0.99, 1.10) 0.105 
cg19124225 chr6 31545836 TNF 3'UTR Weak transcription 0.85 (0.77, 0.89) 0.016 0.842 1.05 (1.01, 1.08) 0.010 1.03 (0.99, 1.08) 0.127 
cg02137984 chr6 31545898 TNF 3'UTR Weak transcription 0.88 (0.84, 0.91) -0.457 0.000 1.04 (0.99, 1.09) 0.129 1.04 (0.98, 1.11) 0.156 
cg06825478 chr6 31546067 TNF 3'UTR Weak transcription 0.82 (0.77, 0.88) -0.348 0.000 1.02 (0.98, 1.05) 0.309 1.01 (0.97, 1.05) 0.783 
cg17755321 chr6 31546085 TNF 3'UTR Weak transcription 0.90 (0.86, 0.92) -0.389 0.000 0.99 (0.94, 1.04) 0.686 1.00 (0.95, 1.07) 0.896 
             
IL6             
cg17067544 chr7 22765321 IL6 TSS1500 
Weak Repressed 
PolyComb 0.50 (0.39, 0.62) 0.281 0.000 0.99 (0.98, 1.01) 0.217 0.99 (0.97, 1.01) 0.288 
cg10140158 chr7 22765750 IL6 TSS1500 Enhancers 0.82 (0.73, 0.86) 0.107 0.183 1.02 (1.00, 1.04) 0.095 1.01 (0.99, 1.04) 0.345 
cg01770232 chr7 22766155 IL6 TSS1500 Enhancers 0.17 (0.14, 0.21) 0.190 0.017 1.01 (0.97, 1.06) 0.525 0.99 (0.94, 1.04) 0.637 
cg26061582 chr7 22766209 IL6 TSS1500 Enhancers 0.05 (0.04, 0.07) 0.050 0.537 0.91 (0.83, 1.00) 0.057 0.94 (0.85, 1.05) 0.281 
cg05472934 chr7 22766657 IL6 TSS200 Enhancers 0.05 (0.04, 0.06) 0.212 0.008 0.96 (0.89, 1.03) 0.251 0.96 (0.88, 1.05) 0.405 
cg00087425 chr7 22766829 IL6 1stExon;5'UTR Flanking Active TSS 0.16 (0.10, 0.30) -0.127 0.112 1.00 (0.99, 1.02) 0.834 1.02 (1.00, 1.04) 0.084 
cg15703690 chr7 22766992 IL6 Body Flanking Active TSS 0.16 (0.12, 0.21) -0.072 0.371 1.01 (0.99, 1.03) 0.189 1.03 (1.00, 1.05) 0.024 
cg13104385 chr7 22767384 IL6 Body Flanking Active TSS 0.61 (0.54, 0.67) -0.256 0.001 1.01 (0.98, 1.03) 0.608 1.00 (0.97, 1.03) 0.915 
cg05265849 chr7 22767390 IL6 Body Flanking Active TSS 0.54 (0.44, 0.63) -0.338 0.000 1.01 (0.99, 1.02) 0.457 0.99 (0.97, 1.01) 0.544 
cg07998387 chr7 22767571 IL6 Body Quiescent/Low 0.63 (0.56, 0.68) 0.052 0.521 1.02 (1.00, 1.04) 0.028 1.01 (0.99, 1.04) 0.423 
cg02335517 chr7 22768438 IL6 Body Quiescent/Low 0.93 (0.92, 0.94) 0.012 0.877 1.02 (0.97, 1.07) 0.490 0.98 (0.92, 1.04) 0.500 
             
TGFB3             
cg20096775 chr14 76425468 TGFB3 3'UTR Strong transcription 0.81 (0.79, 0.83) -0.263 0.001 0.98 (0.90, 1.06) 0.558 1.01 (0.92, 1.11) 0.795 
cg10782206 chr14 76445988 TGFB3 Body Active TSS 0.75 (0.65, 0.82) -0.229 0.004 0.99 (0.98, 1.01) 0.539 1.00 (0.97, 1.03) 0.984 
cg06958766 chr14 76446087 TGFB3 Body Active TSS 0.69 (0.55, 0.78) -0.163 0.041 1.01 (1.00, 1.03) 0.115 1.01 (0.99, 1.03) 0.469 
cg13121428 chr14 76446161 TGFB3 Body Active TSS 0.79 (0.73, 0.84) -0.415 0.000 0.97 (0.94, 1.00) 0.030 0.98 (0.95, 1.02) 0.316 
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cg02057912 chr14 76446433 TGFB3 Body Active TSS 0.48 (0.43, 0.55) -0.199 0.012 1.01 (0.99, 1.03) 0.250 1.00 (0.98, 1.03) 0.884 
cg24696715 chr14 76446681 TGFB3 Body Flanking Active TSS 0.56 (0.51, 0.63) -0.466 0.000 0.96 (0.93, 0.99) 0.016 0.98 (0.95, 1.02) 0.275 
cg18298494 chr14 76447327 TGFB3 1stExon;5'UTR Flanking Active TSS 0.57 (0.49, 0.63) -0.282 0.000 0.98 (0.95, 1.00) 0.043 0.99 (0.97, 1.02) 0.565 
cg08615333 chr14 76447413 TGFB3 1stExon;5'UTR Flanking Active TSS 0.63 (0.53, 0.71) -0.167 0.036 0.98 (0.97, 1.00) 0.054 0.99 (0.97, 1.01) 0.516 
cg17928876 chr14 76447431 TGFB3 1stExon;5'UTR Flanking Active TSS 0.56 (0.49, 0.64) -0.026 0.751 0.99 (0.97, 1.01) 0.514 1.00 (0.98, 1.02) 0.691 
cg13643339 chr14 76447949 TGFB3 1stExon;5'UTR Active TSS 0.03 (0.02, 0.03) 0.074 0.360 1.08 (0.86, 1.35) 0.507 1.08 (0.83, 1.39) 0.568 
cg03395898 chr14 76448011 TGFB3 1stExon;5'UTR Active TSS 0.17 (0.12, 0.22) 0.256 0.001 0.97 (0.94, 1.00) 0.093 0.99 (0.95, 1.03) 0.580 
cg16187883 chr14 76448191 TGFB3 TSS200 Active TSS 0.14 (0.11, 0.17) 0.454 0.000 1.02 (0.95, 1.09) 0.559 1.00 (0.93, 1.08) 0.905 
cg16292972 chr14 76448509 TGFB3 TSS1500 Active TSS 0.04 (0.03, 0.04) 0.066 0.414 1.18 (0.88, 1.59) 0.265 1.45 (1.01, 2.09) 0.044 
cg05864191 chr14 76448933 TGFB3 TSS1500 Active TSS 0.03 (0.02, 0.03) -0.052 0.517 0.95 (0.66, 1.37) 0.785 0.87 (0.54, 1.41) 0.574 
cg16411863 chr14 76448962 TGFB3 TSS1500 Active TSS 0.02 (0.02, 0.03) -0.059 0.464 1.15 (0.84, 1.57) 0.388 1.60 (0.80, 3.21) 0.187 
cg10502508 chr14 76449243 TGFB3 TSS1500 Flanking Active TSS 0.04 (0.03, 0.05) 0.113 0.158 0.92 (0.72, 1.16) 0.462 0.90 (0.69, 1.17) 0.441 
             
TGFB1             
cg04614483 chr19 41836950 TGFB1 3'UTR Weak transcription 0.49 (0.41, 0.55) 0.519 0.000 1.03 (1.01, 1.05) 0.016 1.01 (0.98, 1.04) 0.478 
cg11037750 chr19 41837015 TGFB1 Body Weak transcription 0.72 (0.63, 0.77) 0.506 0.000 1.04 (1.01, 1.06) 0.002 1.02 (1.00, 1.05) 0.087 
cg09926389 chr19 41837123 TGFB1 Body Weak transcription 0.76 (0.62, 0.88) 0.438 0.000 1.03 (1.01, 1.04) 0.000 1.02 (1.00, 1.03) 0.053 
cg03630756 chr19 41839506 TGFB1 Body Weak transcription 0.93 (0.92, 0.94) 0.054 0.500 1.06 (0.94, 1.20) 0.355 0.85 (0.68, 1.06) 0.144 
cg20748073 chr19 41842629 TGFB1 Body Weak transcription 0.88 (0.86, 0.89) 0.022 0.782 0.98 (0.92, 1.04) 0.481 0.98 (0.91, 1.06) 0.650 
cg27540367 chr19 41848134 TGFB1 Body Enhancers 0.58 (0.54, 0.64) -0.248 0.002 0.98 (0.95, 1.02) 0.377 0.99 (0.95, 1.03) 0.543 
cg15735736 chr19 41854950 TGFB1 Body Weak transcription 0.41 (0.33, 0.49) -0.092 0.251 0.98 (0.96, 1.00) 0.019 0.99 (0.97, 1.01) 0.376 
cg15726807 chr19 41857198 TGFB1 Body Flanking Active TSS 0.09 (0.07, 0.12) -0.255 0.001 0.96 (0.92, 1.00) 0.079 1.01 (0.95, 1.08) 0.649 
cg13342441 chr19 41857250 TGFB1 Body Flanking Active TSS 0.04 (0.04, 0.05) -0.348 0.000 0.87 (0.74, 1.03) 0.107 0.92 (0.78, 1.10) 0.364 
cg21198010 chr19 41857456 TGFB1 Body Flanking Active TSS 0.03 (0.03, 0.04) -0.057 0.481 1.09 (0.78, 1.52) 0.630 1.37 (0.95, 1.96) 0.091 
cg19580847 chr19 41857554 TGFB1 Body Flanking Active TSS 0.03 (0.03, 0.04) 0.127 0.112 0.96 (0.79, 1.16) 0.650 0.97 (0.83, 1.14) 0.748 
cg03313751 chr19 41857626 TGFB1 Body Flanking Active TSS 0.03 (0.03, 0.04) -0.295 0.000 1.64 (1.17, 2.30) 0.004 1.62 (1.14, 2.31) 0.007 
cg18236665 chr19 41858816 TGFB1 1stExon Flanking Active TSS 0.03 (0.03, 0.04) -0.073 0.361 1.02 (0.81, 1.29) 0.846 1.00 (0.78, 1.28) 0.994 
cg00389176 chr19 41859014 TGFB1 1stExon;5'UTR Flanking Active TSS 0.06 (0.05, 0.06) 0.012 0.878 1.23 (0.98, 1.53) 0.074 1.07 (0.79, 1.45) 0.670 
cg01107031 chr19 41859159 TGFB1 1stExon;5'UTR Flanking Active TSS 0.03 (0.03, 0.04) -0.190 0.017 0.96 (0.91, 1.02) 0.237 0.97 (0.90, 1.04) 0.411 
cg13464744 chr19 41859304 TGFB1 1stExon;5'UTR Flanking Active TSS 0.03 (0.03, 0.04) -0.050 0.531 1.18 (0.81, 1.72) 0.376 0.95 (0.61, 1.46) 0.804 
cg11714801 chr19 41859555 TGFB1 1stExon;5'UTR Active TSS 0.07 (0.06, 0.09) 0.100 0.211 1.02 (0.97, 1.08) 0.381 1.02 (0.92, 1.14) 0.674 
cg05637188 chr19 41860004 TGFB1 TSS200 Flanking Active TSS 0.02 (0.02, 0.02) 0.030 0.707 0.93 (0.28, 3.07) 0.902 0.92 (0.26, 3.21) 0.896 
cg04547554 chr19 41860013 TGFB1 TSS200 Flanking Active TSS 0.01 (0.01, 0.02) -0.209 0.009 0.82 (0.33, 2.04) 0.664 2.14 (0.59, 7.74) 0.247 
cg23275502 chr19 41860019 TGFB1 TSS200 Flanking Active TSS 0.01 (0.01, 0.02) -0.179 0.025 1.02 (0.53, 1.96) 0.945 1.76 (0.59, 5.24) 0.313 
cg20410381 chr19 41860082 TGFB1 TSS1500 Flanking Active TSS 0.05 (0.04, 0.05) -0.036 0.652 1.02 (0.86, 1.22) 0.812 1.13 (0.90, 1.42) 0.306 
cg24767336 chr19 41860095 TGFB1 TSS1500 Flanking Active TSS 0.03 (0.02, 0.03) -0.223 0.005 1.15 (0.92, 1.44) 0.211 1.46 (1.06, 2.02) 0.020 
cg09489285 chr19 41860454 TGFB1 3'UTR;TSS1500 Enhancers 0.90 (0.88, 0.92) -0.052 0.520 1.03 (0.97, 1.09) 0.382 1.01 (0.94, 1.10) 0.726 
cg16883145 chr19 41860619 TGFB1 Body;TSS1500 Enhancers 0.85 (0.83, 0.87) 0.035 0.666 0.99 (0.92, 1.05) 0.696 0.97 (0.92, 1.03) 0.379 
cg25975823 chr19 41860824 TGFB1 Body;TSS1500 Weak transcription 0.82 (0.80, 0.84) 0.148 0.064 1.02 (0.96, 1.09) 0.482 1.01 (0.94, 1.08) 0.844 
1Adjusted for age and sex 
2Adjusted for age, sex, stage and five surrogate variables 
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Table 5-4. Hazard ratios and 95% confidence intervals for the associations between average methylation across CpG loci in 
specific genomic regions and pancreatic cancer survival 
 
   Expression Minimally adjusted1 Fully adjusted2 
Genomic region 
N CpG 
loci 
Beta value, 
median (IQR) 
Spearman's 
correlation 
coefficient p HR (95% CI) p HR (95% CI) p 
IL10         
Entire gene 6 0.79 (0.75, 0.83) -0.474 <0.001 0.97 (0.93, 1.00) 0.069 0.98 (0.93, 1.02) 0.254 
Weak transcription 1 0.75 (0.68, 0.81) -0.253 0.001 0.96 (0.93, 0.98) 0.001 0.97 (0.94, 1.00) 0.027 
Quiescent/Low 5 0.81 (0.76, 0.85) -0.495 <0.001 0.98 (0.94, 1.01) 0.218 0.98 (0.94, 1.03) 0.448 
         
TGFB2         
Entire gene 23 0.22 (0.20, 0.23) -0.320 <0.001 0.96 (0.89, 1.04) 0.33 1.01 (0.91, 1.11) 0.91 
Active TSS 8 0.05 (0.04, 0.06) -0.280 <0.001 0.97 (0.84, 1.11) 0.631 1.05 (0.89, 1.23) 0.579 
Flanking Active TSS 8 0.06 (0.05, 0.08) -0.351 <0.001 0.96 (0.90, 1.02) 0.206 1.00 (0.93, 1.07) 0.900 
Weak transcription 5 0.60 (0.56, 0.65) -0.382 <0.001 0.98 (0.94, 1.01) 0.157 0.99 (0.95, 1.03) 0.633 
Enhancers 1 0.34 (0.26, 0.43) 0.143 0.074 1.02 (1.00, 1.04) 0.097 1.01 (0.99, 1.04) 0.298 
Quiescent/Low 1 0.72 (0.65, 0.80) 0.311 <0.001 1.01 (0.99, 1.03) 0.187 1.01 (0.99, 1.04) 0.386 
         
IL83         
Entire gene 2 0.48 (0.46, 0.50) -0.008 0.926 0.97 (0.90, 1.05) 0.495 0.96 (0.88, 1.06) 0.466 
         
TNF         
Entire gene 28 0.60 (0.57, 0.64) -0.424 <0.001 1.04 (1.00, 1.10) 0.074 1.02 (0.96, 1.09) 0.455 
Weak transcription 9 0.79 (0.74, 0.82) -0.373 <0.001 1.07 (1.02, 1.13) 0.006 1.05 (0.99, 1.12) 0.117 
Quiescent/Low 19 0.52 (0.48, 0.56) -0.400 <0.001 1.02 (0.98, 1.06) 0.394 1.01 (0.96, 1.06) 0.755 
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IL6         
Entire gene 11 0.43 (0.39, 0.45) -0.035 0.662 1.02 (0.98, 1.06) 0.404 1.02 (0.96, 1.07) 0.593 
Flanking Active TSS 4 0.37 (0.32, 0.44) -0.338 <0.001 1.01 (0.99, 1.04) 0.333 1.02 (0.99, 1.05) 0.246 
Enhancers 4 0.27 (0.25, 0.30) 0.183 0.021 1.01 (0.96, 1.06) 0.787 1.01 (0.94, 1.07) 0.861 
Weak Repressed PolyComb 1 0.50 (0.39, 0.62) 0.281 <0.001 0.99 (0.98, 1.01) 0.217 0.99 (0.97, 1.01) 0.288 
Quiescent/Low 2 0.78 (0.74, 0.81) 0.050 0.534 1.04 (1.00, 1.07) 0.045 1.01 (0.97, 1.06) 0.583 
         
TGFB3         
Entire gene 16 0.39 (0.36, 0.42) -0.223 0.005 0.97 (0.93, 1.02) 0.309 0.99 (0.94, 1.05) 0.747 
Active TSS 10 0.31 (0.29, 0.34) -0.171 0.032 1.00 (0.95, 1.06) 0.999 1.00 (0.94, 1.07) 0.934 
Flanking Active TSS 5 0.47 (0.41, 0.53) -0.232 0.003 0.97 (0.94, 1.00) 0.055 0.99 (0.96, 1.02) 0.484 
Strong transcription 1 0.81 (0.79, 0.83) -0.263 0.001 0.98 (0.90, 1.06) 0.558 1.01 (0.92, 1.11) 0.795 
         
TGFB1         
Entire gene 25 0.32 (0.31, 0.33) 0.330 <0.001 1.16 (1.01, 1.33) 0.040 1.11 (0.93, 1.32) 0.260 
Active TSS 1 0.07 (0.06, 0.09) 0.100 0.211 1.02 (0.97, 1.08) 0.381 1.02 (0.92, 1.14) 0.674 
Flanking Active TSS 14 0.04 (0.03, 0.04) -0.380 <0.001 0.84 (0.65, 1.08) 0.174 1.02 (0.74, 1.42) 0.902 
Weak transcription 7 0.71 (0.67, 0.75) 0.477 <0.001 1.06 (1.01, 1.10) 0.010 1.03 (0.98, 1.08) 0.236 
Enhancers 3 0.78 (0.75, 0.80) -0.173 0.030 0.99 (0.91, 1.07) 0.741 0.96 (0.87, 1.06) 0.443 
1Adjusted for age and sex 
2Adjusted for age, sex, stage and five surrogate variables 
3Both CpG loci for IL8 were associated with the Quiescent/Low chromatin state 
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FIGURES 
Figure 1-1. Conceptual framework of dissertation aims 
 
 71 
 
Figure 4-1. Flowchart of Kaiser Permanente Southern California study cohort 
 
 
   
KPSC members aged 
45-90 from 2006-2016
N=2,919,252
- Missing BMI (N=113,724)
- Missing smoking (N=131,821)
- Missing alcohol (N=296,111)
No diabetes
N=1,055,996
Prevalent diabetes
N=332,932
Study cohort
N=1,499,627
Pancreatic cancer
N=937
Pancreatic cancer
N=759
Members with 2+ years 
membership
N=2,023,927
- <2 yrs continuous membership 
(N=895,325)
Eligible patients
N=1,639,828
- No HbA1c or glucose test (N=67,486)
- Other/unknown ethnicity (N=80,801)
- Previous pancreatic cancer (N=523)
Incident diabetes
N=110,699
Pancreatic cancer
N=306
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A
B
C
Figure 4-2. Boxplots of (a) 
fasting glucose, (b) HbA1c and 
(c) weight values before and at 
diabetes diagnosis, across 
pancreatic cancer status 
 
Within boxplot, solid diamond 
indicates mean value, solid line 
indicates median.  
 
P-values indicate results from a 
Mann-Whitney U test comparing 
distributions between individuals 
with and without pancreatic cancer 
in given time window. 
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A
B
C
Figure 4-3. Boxplots of the 
percent differences in (a) fasting 
glucose, (b) HbA1c and (c) 
weight between the time before 
and at diabetes diagnosis, across 
pancreatic cancer status and 
race/ethnicity  
 
Within boxplot, solid diamond 
indicates mean value, solid line 
indicates median.  
 
P-values under subgroup indicate 
results from a Mann-Whitney U 
test comparing distributions 
between individuals with and 
without pancreatic cancer in given 
subgroup.  
 
P-heterogeneity indicates overall 
heterogeneity for mean percent 
difference across pancreatic cancer 
status and race/ethnicity. 
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Figure 5-1. Genomic information, Spearman correlation coefficients for expression, and 
hazard ratios and 95% confidence intervals for selected CpG loci in TGFβ1. 
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Figure 5-2. Genomic information, Spearman correlation coefficients for expression, and 
hazard ratios and 95% confidence intervals for selected CpG loci in TGFβ2. 
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Figure 5-3. Genomic information, Spearman correlation coefficients for expression, and 
hazard ratios and 95% confidence intervals for selected CpG loci in TGFβ3. 
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Figure 5-4. Genomic information, Spearman correlation coefficients for expression, and 
hazard ratios and 95% confidence intervals for selected CpG loci in IL6. 
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Figure 5-5. Genomic information, Spearman correlation coefficients for expression, and 
hazard ratios and 95% confidence intervals for CpG loci in IL10. 
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